Download lynda s. welage - University of Minnesota College of Pharmacy

LYNDA S. WELAGE
BUSINESS ADDRESS:
University of New Mexico
College of Pharmacy
2502 Marble NE
1 University of New Mexico
Albuquerque, New Mexico 87131
(505) 272-0906 (Phone)
(505) 272-5782 (Fax)
EDUCATION AND TRAINING
1983 – 1985
Postdoctoral Fellowship in Clinical Pharmacokinetics
The Clinical Pharmacokinetics Laboratory
Millard Fillmore Hospital
Buffalo, New York
1981 – 1983
Doctor of Pharmacy
State University of New York at Buffalo Division of Clinical Pharmacy
Science Buffalo, New York
1976 – 1981
Bachelor of Science in Pharmacy
University of Michigan College of Pharmacy Ann Arbor, Michigan
PROFESSIONAL EXPERIENCE
2011 – present
Dean
University of New Mexico
College of Pharmacy
Albuquerque, New Mexico
2011 – present
Professor
University of New Mexico
College of Pharmacy
Albuquerque, New Mexico
2011 – present
Professor Emeritus
University of Michigan
College of Pharmacy
Ann Arbor, Michigan
2009 – 2011
Associate Director
Michigan Institute for Clinical and Health Research
University of Michigan
Ann Arbor, Michigan
2009 – 2011
Continuing Education Administrator
University of Michigan
College of Pharmacy
Ann Arbor, Michigan
L. S. Welage - 2
2007 – 2011
Director (2009-2011)/Co-director (2007-2009)
Education, Mentoring and Career Development Programs
Michigan Institute for Clinical Health Research
University of Michigan
Ann Arbor, Michigan
2004 – 2011
Associate Dean for Academic Affairs
University of Michigan
College of Pharmacy
Ann Arbor, Michigan
2004 – 2011
Professor of Pharmacy
University of Michigan College of Pharmacy
Department of Clinical Sciences
Ann Arbor, Michigan
1995 – 2004
Associate Professor of Pharmacy
University of Michigan
College of Pharmacy
Department of Clinical Sciences
Ann Arbor, Michigan
2006 – 2011
Clinical Pharmacist
Residency Program - Research and Teaching Series Coordinator
Department of Pharmacy Services
University of Michigan Hospitals
Ann Arbor, Michigan
1988 – 2006
Clinical Pharmacist
Surgery/Critical Care
Department of Pharmacy Services
University of Michigan Hospitals
Ann Arbor, Michigan
1988 – 1995
Assistant Professor of Pharmacy
University of Michigan
College of Pharmacy
Ann Arbor, Michigan
1986 – 1988
Program Director, Critical Care
The Clinical Pharmacokinetics Laboratory
Millard Fillmore Hospital
1986 – 1988
Clinical Pharmacist
Surgical Intensive Care Unit
Department of Pharmacy
Millard Fillmore Hospital
Buffalo, New York
1986 – 1988
Clinical Assistant Professor
Department of Pharmacy
State University of New York at Buffalo
Buffalo, New York
L. S. Welage - 3
1985 – 1986
Clinical Instructor
Department of Pharmacy
State University of New York at Buffalo
Buffalo, New York
Licensure:
State of Michigan
ADMINISTRATIVE EXPERIENCE
2011 – present
Dean, University of New Mexico, College of Pharmacy, Albuquerque,
New Mexico
Highlights of Activities:
 Financial: Responsible for all aspects of financial operations ($19 M
budget) for the College of Pharmacy
 Research and Scholarly Productivity:
 Invested in research office infrastructure, grant writing workshops,
mentoring programs and pilot grants.
 Research funding increased by 200% over past five years, from
$3,431,601 in FY12 to $10,286,045 in FY16.
 UNM College of Pharmacy research rankings rose from 34th in
FY11 to 21st in FY15 based on NIH-funded awards and from 34th
to 28th based on total extramural funding.
 Organized and hosted the 7th and 8th international Metal Toxicity
and Carcinogenesis Conference in 2012 and 2014.
 Education/Accreditation:
 Received full 8-year re-accreditation of our Doctor of Pharmacy
program, fully meeting all 30 standards with no deficiencies.
 Strong Doctor of Pharmacy (n=325), and graduate (MS and PhD)
programs in Pharmaceutical Sciences (n=13). In addition, the
College partners with the School of Medicine on graduate degrees
in Biomedical Sciences with emphasis in Toxicology and
Environmental Health and with the College of Arts and Sciences
and the College of Engineering on the Interdisciplinary
Nanoscience and Microsystems graduate program. New dual
PharmD/MS programs in Pharmaceutical Sciences with two
concentrations were approved in 2016.
 The Doctor of Pharmacy curriculum is being transformed to adapt
to changes in the healthcare as well as education including a
significant expansion of interprofessional education and practice
activities (new curriculum launches Fall 2017).
 New Clinical Initiatives:
 Developed an infrastructure to support the expanded clinical
service enterprise. Services include pharmacy practice
management, formulary management, 340B consulting,
medication therapy management, disease state management, and
transitions of care. The clinical services also serve as scholarly
laboratories for new models of practice and education.
 In Fall 2014, the College opened the Medication Therapy Call
Center which aims to optimize medication therapy management
for individuals throughout the state.
L. S. Welage - 4


College faculty have continued to work with the Board of
Pharmacy and professional organizations to expand the scope of
pharmacy practice in the state. Since 2011, new Board of
Pharmacy-approved protocols include TB testing, naloxone
prescribing, and support medications for travelers going to foreign
countries.
Recognized as the birthplace for radiopharmacy, the College
proudly re-opened its radiopharmacy which serves as an
environment to train students while also providing clinical services
and radioisotopes to local imaging centers.
 Development and Alumni Engagement:
 Established a “New Alumni Council” to compliment the Dean’s
Council which is composed of Papiani members and Distinguished
alumni. The New Alumni Council aims to better engage more
recent graduates and focus on support of current students.
 Launched new giving initiatives including those linked to our 70th
Anniversary celebrations in 2015, as well as the Circle of Joy
which encourages new donors to provide both endowed and
annual giving to support our students.
 The College’s endowments grew by 7% over the past 5 years.
 Faculty Evaluation and Compensation Systems: Implemented a new
faculty performance evaluation system as well as a new faculty
compensation plan that values excellence and compensates faculty for
performance as well as added work.
 Strategic Planning: Developed and implemented the College of
Pharmacy 2020 strategic plan that aligns with the Health Science
Center and University strategic priorities. While the College of
Pharmacy strategic plan addresses changes in education and
healthcare, it boldly identifies the College’s future direction, timelines
and key outcome/success metrics. The strategic plan provides a
framework programmatic decision making and financial investment.
 Legislative Advocacy: Worked to restore state funding for New
Mexico Poison and Drug Information Center (February 2012).
Advocated to permanently recognize the need for the New Mexico
Poison and Drug Information Center. This led to the legislators
recognizing the need for the center in state Statute (February 2013). In
2015, advocacy led to a creation of a task force to explore new funding
models for the New Mexico Poison and Drug Information Center via a
Senate Memorial.
 Faculty Development and Mentoring:
 Provided leadership in the Faculty of Color Pilot Mentoring, the
Faculty of Color Leadership and the Medical Leadership Academy
Programs. Working to provide centralized faculty development
and mentoring resources across the Health Science Center.
 Charged a College of Pharmacy Faculty Development Committee
to revise mentoring program as well as the process for evaluating
teaching. The Faculty Development Committee also identified
professional development needs and launched an RFP to support
faculty development.
L. S. Welage - 5
 Social Accountability:
 As part of the Health Science Center, the College is working to
fulfill vision 2020 which states, that the University of New Mexico
Health Science Center will make more progress on minimizing
health disparities and enhancing health equity than any other state.
 In 2012, the College launched its first Community Outreach Day
and has continued this. On this day students provide community
service (health fairs, immunizations, education) to more than 6000
individuals throughout the state.
 Students have won a variety of awards for their community
outreach activities especially regarding Generation Rx and Project
Immunizations.

The New Mexico Poison and Drug Information Center (NMPDIC)
provides services to individuals throughout New Mexico, by
responding to more than 26,000 calls annually, providing
consultations to health care professionals and educating the
community regarding poison prevention.
2009 – 2011
Associate Director, Michigan Institute for Clinical and Health Research,
University of Michigan, Ann Arbor, Michigan
Highlights of Activities:
 As one of eight Associate Directors for the Michigan Institute for
Clinical and Health Research worked with the principal
investigator/director of the institute to identify, implement and evaluate
institute priorities.
 Worked with the leadership team to prepare the CTSA renewal (2011)
which was successfully funded.
 Contributed to the national CTSA consortium initiatives.
2007 - 2009
Director (2009-2011)/Co-director (2007-2009) of the Education, Mentoring
and Career Development Programs, University of Michigan, Ann Arbor,
Michigan
Highlights of Activities:
 Oversaw all Education, Career Development and Mentoring activities.
 Worked in an interdisciplinary manner to bring together faculty and
staff from across the university (19 different schools, colleges and
institutes) to forge the development of innovative, transformative
educational programs for translational researchers.
 Offered a diverse educational portfolio which aimed to meet the needs
of all clinical and translational research team members including
professional students, graduate students, faculty, clinical practitioners
and research staff.
2004 – 2011
Associate Dean for Academic Affairs, College of Pharmacy, University of
Michigan, Ann Arbor, Michigan
Highlights of Activities:
 Responsible for overseeing all aspects of the professional program.
L. S. Welage - 6
 Chaired the ACPE Self-Study and worked to ensure that the process
was inclusive, evidence based and transparent. The self-study led to
full accreditation (8 years) with noteworthy practice being cited for
standards 14, 22, and 23.
TEACHING EXPERIENCE
Course Coordination
2014 – present
Instructor of Record, Self-Directed Supplementary Pharmacy Education
(Pharm 740)
University of New Mexico, College of Pharmacy
2013 – present
Instructor of Record, Opportunities in Pharmacy (Pharm 798)
University of New Mexico, College of Pharmacy
2010 – 2011
Course Coordinator, Introduction to Pharmacy (P402)
University of Michigan, College of Pharmacy
2007
Course Coordinator, Service Learning for Health Professionals (P425)
University of Michigan, College of Pharmacy
2007
Course Coordinator, Contemporary Issues and Controversies in Medication
Use (UC 151)
University of Michigan, Literature Science and Arts
2003 – 2010
Course Coordinator, Evidence Based Medicine (P330)
University of Michigan, College of Pharmacy
2003 – 2006
Course Coordinator, Pharmaceutical Care II (P352)
University of Michigan, College of Pharmacy
2000 – 2008
Course Coordinator, Clinical Trials and Drug Development (INTMED
602/P602)
University of Michigan, Medical School and University of Michigan,
College of Pharmacy
2000 – 2002
Course Coordinator, Opportunities in Pharmacy (P550)
University of Michigan, College of Pharmacy
1999 – 2002
Course Coordinator, Pathophysiology & Therapeutics (P531)
University of Michigan, College of Pharmacy
1999 – 2002
Course Coordinator, Pharmaceutical Care IV (P511)
University of Michigan, College of Pharmacy
1998 – 1999
Course Coordinator, Pathophysiology & Therapeutics (P532)
University of Michigan, College of Pharmacy
1998 – 1999
Course Coordinator, Patient Monitoring (P586)
University of Michigan, College of Pharmacy
1998 – 1998
Course Coordinator, Patient Monitoring (P585)
University of Michigan, College of Pharmacy
L. S. Welage - 7
Lecturer/Discussion Leader
2015 – present
Lecturer, Introduction to Pharmacy Practice (Pharm 709)
University of New Mexico, College of Pharmacy
2014
Guest Facilitator, Research Design and Analysis (Pharm 547)
University of New Mexico, College of Pharmacy
2014 – 2015
Lecturer, Pharmacy Healthcare Management and Economics (Pharm 760)
University of New Mexico, College of Pharmacy
2013 – present
Lecturer, Opportunities in Pharmacy (Pharm 798)
University of New Mexico, College of Pharmacy
2010 – 2011
Lecturer, Introduction to Pharmacy (P402)
University of Michigan, College of Pharmacy
2007 – 2008
Lecturer, Service Learning for Health Professionals (P425)
University of Michigan, College of Pharmacy
2007
Lecturer, Contemporary Issues and Controversies in Medication Use (UC
151)
University of Michigan, Literature Science and Arts
2007 – 2011
Preceptor, Academic Teaching Rotation
Pharmacy Residents
University of Michigan Hospitals
2007 – 2011
Preceptor, Academic Teaching Rotation
Pharmacy Students
University of Michigan Hospitals
2005 – 2006
Lecturer, Pharmaceutical Care V (P551)
University of Michigan, College of Pharmacy
2004 – 2007, 2010
Lecturer, Pharmaceutical Care II (P352)
University of Michigan, College of Pharmacy
2004 – 2010
Lecturer, Evidence Based Medicine (P330)
University of Michigan, College of Pharmacy
2000 – 2008
Lecturer, Clinical Trials and Drug Development (INTMED 602/P602)
University of Michigan, Medical School and
University of Michigan, College of Pharmacy
2000 – 2004
Lecturer, Opportunities in Pharmacy (P550)
University of Michigan, College of Pharmacy
1999 – 2003
Lecturer, Pharmaceutical Care III (P486)
University of Michigan, College of Pharmacy
1998 – 2003
Lecturer, Pharmaceutical Care II (P485)
University of Michigan, College of Pharmacy
L. S. Welage - 8
1988 – 2005
Preceptor, Trauma Burn Surgery/Critical Care
Doctor of Pharmacy Candidates
University of Michigan Hospitals
1988 – 2006
Preceptor, Trauma Burn Surgery/Critical Care
Pharmacy Residents
University of Michigan Hospitals
1988 – 2006
Preceptor, Pharm.D. Seminar (P680)
University of Michigan, College of Pharmacy
1988 – 2011
Preceptor, Pharm.D. Investigations (P680)
University of Michigan, College of Pharmacy
2000 – 2002
Lecturer/Facilitator, Pharmaceutical Care IV (P511)
University of Michigan, College of Pharmacy
1998 – 1999
Lecturer, Patient Monitoring (P586)
University of Michigan, College of Pharmacy
1996 – 1998
Lecturer, Patient Monitoring (P585)
University of Michigan, College of Pharmacy
1992 – 1998
Lecturer, Senior Clinical Pharmacology and Therapeutics (LA2A26E)
University of Michigan, Medical School
1991 – 1992
Guest Lecturer, Therapeutics: Gastroesophageal Reflux Disease
Wayne State University, School of Pharmacy
1990 – 1999
Lecturer, Applied Pharmacokinetics (P562)
University of Michigan, College of Pharmacy
1990 – 1995
Instructor, CPR
University of Michigan, College of Pharmacy
1988 – 2002
Lecturer, Pathophysiology & Therapeutics (P531, P532)
University of Michigan, College of Pharmacy
1987 – 1988
Research Preceptor (P569) Doctor of Pharmacy Candidates
State University of New York at Buffalo
1986 – 1988
Preceptor, Surgical Intensive Care Rotation
Doctor of Pharmacy Candidates
State University of New York at Buffalo
1985 – 1988
Preceptor, Pharmacokinetics Rotation
Doctor of Pharmacy Candidates
State University of New York at Buffalo
1982
Undergraduate Lecturer, Clinical Case Studies (PHM 494)
State University of New York at Buffalo
1981 – 1982
Graduate Teaching Assistant, Undergraduate Professional Practice
Laboratory (PHM 432)
State University of New York at Buffalo
L. S. Welage - 9
Post-Doctoral Fellows and Specialty Residents Trained
Training Period
9/1/08-8/30/09
Trainee
Stephen Stout, Pharm.D.
Current Position
Pharmacotherapy Specialist
Lexi-comp, Inc
Hudson, Ohio
1/1/07-6/30/09
Noha Salama, Ph.D.
Assistant Professor
St. Louis College of Pharmacy
St. Louis, Missouri
6/1/05-5/31/07
Jignesh Patel, Pharm.D.
Clinical Pharmacist Rochester
General Hospital
Rochester, New York
10/1/04-8/30/05
Co Pham, Pharm.D.
Scientist
Canadian Health Agency
Ottawa, Ontario, Canada
7/6/04-6/30/07
Jace Nielsen, Pharm.D.
Research Scientist Pharmacometrics
Ann Arbor, Michigan
7/6/99-6/30/02
David Foster, Pharm.D.
Associate Professor
Purdue University, School of
Pharmacy and Pharmacal Sciences
D711 Myers Building
1001 W. Tenth Street
Indianapolis, Indiana
7/1/98-6/30/00
Jeffrey Gonzales, Pharm.D., BCPS
Assistant Professor
Department of Pharmacy Practice
and
Science
University of Maryland School of
Pharmacy Baltimore, Maryland
7/15/96-6/30/99
Brien Neudeck, Pharm.D.
Medical Science Liaison
Medtronics
West Linn, Oregon
7/1/96-6/30/98
Marc Reichert, Pharm.D. BCPS
Pharmaceutical Care Coordinator
Wake Forest
Specialty Resident, Critical Care
University Baptist Medical Center
Medical Center Blvd. WinstonSalem, North Carolina
THESIS COMMITTEES
October 2002 - December 2003
Sujatha Menon, MS., Ph.D.
Thesis: “Modeling Time-Dependent Oral Drug Absorption.”
October 2001 - August 2003
Daniel Streetman, Pharm. D., M.S.
Thesis: “Causes of Steroid Resistance in Pediatric Nephrotic
Syndrome.”
L. S. Welage - 10
October 2001 - August 2003
Jeffrey Ellis, Pharm.D., M.S.
Thesis: “Sub-optimal Statin Compliance in Primary and Secondary
Prevention Populations: Should We Target Patients With the Most to
Gain?”
October 1999 - August 2001
Ellen Mozurkewich, MD
Thesis: “A Randomized Comparison of Oral Misoprostol and
Oxytocin for Premature Rupture of Membranes at Term.”
September 1994 - Summer 2000
Sally Choe, Ph.D.
Thesis: “Analysis of Time-Dependent Oral Drug Absorption.”
HONORS AND AWARDS

P4 Teaching Appreciation Award (2007-2008)

AACP Leadership Fellow (2006- 2007)

Committee on Institutional Cooperation (CIC) Academic Leadership Program (2004 – 2005)

P1 Teaching Appreciation Award (2003- 2004)

Computer World Honors Collection, Smithsonian National Museum of American History (2003)

International Who’s Who Historical Society (2003)

Society of Critical Care Medicine President's Citation (1996, 1997, 1998, 2000, 2001, 2002, 2004, 2005)

University of Michigan Road Scholar (2002)

Excellence in Teaching, University of Michigan College of Pharmacy (2000)

Fellow American College Clinical Pharmacy (elected in 1998)

Sandoz Pharmacy Award (1983)
Board Appointments

ACCP Research Institute Board of Trustees (October 2014- present)

Tricore Reference Laboratory Board of Directors (2015- present)
GRANTS
NIH Training Grants:
2004-2007
NIH Training Grant 5K30HL004108-03. (Principal Investigator: David Schteingart, M.D.)
2003-2008
Mentored Clinical Research Scholar Program Award (K12), (Principal Investigator: David
Schteingart, M.D.)
NIH Training Grant 5K30HL004108-03, (Principal Investigator: David Schteingart, M.D.)
1999 - 2004
Grants Funded:
FDA. “Correlation of Mesalamine Pharmacokinetics with Local Availability.” Principal Investigator: Duxin Sun,
Ph.D., Co-investigators: Lynda Welage, Pharm.D., Gordon Amidon, Ph.D, William Hasler, MD., 9/10-8/13,
$.900,000 HHSF223201000082C.
L. S. Welage - 11
MICHR-MCRU. “Comparison of Cardiovascular Risk Among the Young in Developed and Developing Nations.”
Principal Investigator: Barry Bleske, PharmD., U.S. Co-investigators: Steve Erickson, Pharm.D., Nabil Khalidi,
Pharm.D., Michael Shea, M.D., Lynda Welage, Pharm.D., 4/08-4/10, $10,000.
NIH. “Clinical Translational Science Award.” Principal Investigator: Daniel Clauw, M.D. 9/07-8/11,
$55,000,000. UL1RR024986 (45% effort as director MICHR research education and mentoring programs).
NIH. “P-glycoprotein and Steroid-Resistant Nephrotic Syndrome (R21).” Principal Investigators: Daniel
Streetman, Pharm.D., Lynda Welage, Pharm.D., Co-investigators: Richard Smoyer, M.D., 9/04 -8/07, $420,750.
AstraZeneca- investigator initiated. “The Effect of Paroxetine and Sildenafil on the Pharmacokinetics of Metoprolol
and Carvedilol.” Principal Investigator: Barry Bleske, Pharm.D., Co-investigator: Lynda Welage, Pharm.D., 5/044/05, $343,776.
Center for Research on Learning and Teaching. “The Pharmacist: An Interactive Web-based Program to Enhance
Skill Development.” Principal Investigator: Lynda Welage, Pharm.D., 1/04- 6/05, $5,994.
Glaxo Smith Kline- investigator initiated. “Outcome and Cost Analysis of Prolonged Postoperative Ileus after Open
Abdominal Surgery.” Principal Investigator: Mary Dimo, Pharm.D., Co-investigators: Lynda Welage, Pharm.D.,
Michael Kraft, Pharm.D., Wendy Wahl, M.D., 7/03- 6/04, $52,457.
National Kidney Foundation of Michigan. “Causes of Steroid Resistance in Pediatric Nephrotic Syndrome.”
Principal Investigator: Daniel Streetman, Pharm.D., Co-investigators: Lynda Welage, Pharm.D., William Smoyer,
M.D., 8/02-7/03, $29,746.
General Clinical Research Center. “Evaluation of the Impact of Gender on p-Glycoprotein Expression.” Principal
Investigator: Lynda Welage, Pharm.D., Co-investigators: Daniel Streetman, Pharm.D., James Scheiman, M.D.,
12/1/01 - present.
Clinical Research Resource Committee. “Genetic Control of P-glycoprotein Content and Expression in
Lymphoocytes from Adolescents and Adults.” Principal Investigator: Daniel Streetman, Pharm.D., Co-investigator:
Lynda Welage, Pharm.D., William Smoyer, M.D., 12/01- present, $24,128.
American College of Clinical Pharmacy. Wyeth Ayerst-Women’s Health Award. “Evaluation of the Impact of
Gender on p-Glycoprotein Expression.” Principal Investigator: Lynda Welage, Pharm.D., Co-investigators: Daniel
Streetman, Pharm.D., James Scheiman, M.D., 7/01- 6/04 (no cost extension), $10,000.
General Clinical Research Center. “Impact of Microgravity on Drug and Nutrient Absorption.” Principal
Investigator: Gordon Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., James Scheiman, M.D., 2/01present.
General Clinical Research Center. “Evaluation of the Relationship Between Intestinal Permeability and
Bioavailibility for Valacyclovir and Acyclovir in Humans.” Principal Investigator: Gordon Amidon, Ph.D., Coinvestigator: Lynda Welage Pharm.D., Jeffrey Barnett, M.D., 2/00-01/01.
National Aeronautic & Space Administration (NASA). “Impact of Microgravity on Drug and Nutrient Absorption.”
Principal Investigator: Gordon Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Jeffrey Barnett, M.D.,
7/99-10/03, $595,178
American College of Clinical Pharmacy Critical Care Research Fellowship. Principal Investigator: Lynda Welage,
Pharm.D., Fellow: Jeffrey Gonzales, Pharm.D., 7/99-6/00, $22,500.
NIH/NIGMS. “Mucosal Cell Transporters and Enzymes in Drug Delivery.” Principal Investigator: Gordon Amidon,
Ph.D., Co-investigator: Lynda Welage, Pharm.D., Jeffrey Barnett, M.D., James Scheiman, M.D., 4/99-3/03,
$1,624,512.
L. S. Welage - 12
Upjohn Research Award. “Assessment of Intestinal Permeability in a Chronic Model.” Principal Investigator: Lynda
Welage, Pharm.D., 1/98-12/98, $25,000.
General Clinical Research Center. “Evaluation of the Relative Bioavailability of Eprosartan After Delivery to
Various Intestinal Sites in Healthy Volunteers.” Principal Investigator: Lynda Welage, Pharm.D., Co-investigator:
Jeffrey Barnett, M.D., 12/97-7/98.
Port Systems, LLC. “Evaluation of the Relative Bioavailability of Eprosartan After Delivery to Various Intestinal
Sites in Healthy Volunteers.” Principal Investigator: Lynda Welage, Pharm.D., Co-investigator: Jeffrey Barnett,
M.D., 12/97-7/98, $167,323.
General Clinical Research Center. “Evaluation of the Pellet Gastric Emptying Test (PGET).” Prinicipal
Investigator: Gordon Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Jeffrey Barnett, M.D., 10/97-9/98.
American Foundation for Pharmaceutical Education Clinical Pharmacy Post-Pharm.D. Fellowship. "Characteristics
of Intestinal Tranport Mechanisms following Thermal Injury, Principal Investigator: Lynda Welage, Pharm.D.,
Fellow: Brien Neudeck, Pharm.D., 7/97-6/99, $55,000.
Clinical Research Resources Committee. “Alterations in Ofloxacin Absorption in the Critically Ill.” Principal
Investigator: Lynda Welage, Pharm.D., Co-investigator: Brien Neudeck, Pharm.D. 12/96-11/97, $17,166.
Pfizer-Roerig. “Candidemia in the Surgical Intensive Care Unit: Determining Risk Factors, Assessing Costs, A
Case- Matched Control Analysis.” Principal Investigator: Carol Kauffman, M.D., Co-investigator: Lynda Welage,
Pharm.D., 10/95-10/97, $143,208.
General Clinical Research Center. “Pharmacokinetics of Vancomycin When Administered During Hemodialysis
With Cellulose Triacetate Dialyzers.” Principal Investigator: Nancy Mason, Pharm.D., Co-investigators: Lynda
Welage, Pharm.D., Richard Swartz, M.D., 3/96-3/98.
Lilly- investigator initiated. “Pharmacokinetics of Vancomycin When Administered During Hemodialysis With
Cellulose Triacetate Dialyzers.” Principal Investigator: Nancy Mason, Pharm.D., Co-investigators: Lynda Welage,
Pharm.D, Richard Swartz, M.D., 9/96-9/2000 $20,000.
Computer Resources. “Computer Simulated Case Studies to Enhance Clinical Skills Development in Pharmacy.”
Principal Investigator: Lynda Welage, Pharm.D., Co-investigator: Nancy Mason, Pharm.D., 5/96-5/97, $10,000.
Health and Human Services, Department of Health Resources and Services Administration. “Biopharmaceutics
Drug Classification Simplifying Drug Regulation.” Co-principal investigators: Gordon Amidon, Ph.D., and Lynda
Welage, Pharm.D., Co-investigator: Jeffrey Barnett, M.D., 9/95-9/96, $125,000.
National Aeronautic & Space Administration (NASA). “Intestinal Adaptation in Microgravity: Drugs and Nutrient
Absorption.” Principal Investigator: Gordon Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Jeffrey
Barnett, M.D., 12/95-11/97, $199,132.
General Clinical Research Center. “Intestinal Permeability of Cyclosporin A in Humans.” Principal Investigator:
Gordon Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Jeffrey Barnett, M.D., 11/95-10/97.
Pfizer/Roerig - investigator initiated. “Evaluation of Fluconazole versus Amphotericin B Prescribing Patterns.”
Principal Investigator: Lynda Welage, Pharm.D., Co-investigator: Carol Kauffman, M.D., 12/94-12/96, $20,000.
General Clinical Research Center. “Intestinal Permeability of Enalapril in Humans.” Principal Investigator: Gordon
Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Jeffrey Barnett, M.D., 5/95-10/96.
General Clinical Research Center. “Pharmacokinetics of Intraperitoneal Ceftazidime in CAPD.” Principal
Investigator: Nancy Mason, Pharm.D., Co-investigators: Lynda Welage, Pharm.D., Richard Swartz, M.D., 2/952/96.
L. S. Welage - 13
Clinical Research Resource Committee. “Pharmacokinetics of Intraperitoneal Ceftazidime in Continuous
Ambulatory Peritoneal Dialysis.” Principal Investigator: Nancy Mason, Pharm.D., Co-investigators: Lynda Welage,
Pharm.D., Richard Swartz, M.D., 1/95-12/95, $9,060.
Clinical Research Resource Committee. “Economic and Clinical Impact of Two NMB Dosing Strategies.” Principal
Investigator: Lynda Welage, Pharm.D., 1/95-12/95, $8,100.
Michigan Health Care Education and Research Foundation. “Evaluation of Issues Regarding Multisource
Prescription Drug Products.” Principal Investigator: Duane Kirking, Ph.D., Co-investigators: Lynda Welage,
Pharm.D., Frank Ascione, Ph.D., Caroline Gaither, Ph.D., 1/95-12/95, $46,435.
Glaxo Research Institute -investigator initiated. “Continuous versus Intermittent Ceftazidime for Gram
Negative Peritonitis Associated with Continuous Ambulatory Peritoneal Dialysis.” Principal Investigator:
Nancy Mason, Pharm.D., Co-investigators: Lynda Welage, Pharm.D., Richard Swartz, M.D., 3/1/95-3/1/96,
$30,604.
University Hospitals Small Grant Program. “Assessment of the Impact of Two Dosing Methods of Neuromuscular
Blocking Agents on Patient Outcome and Its Potential Financial Implications.” Principal Investigator: Lynda
Welage, Pharm.D., 1/95-12/95, $8,256.
General Clinical Research Center. “Effects of Interdigestive Gastrointestinal Motility and pH on the Oral
Absorption of Ranitidine in Humans.” Principal Investigator: Gordon Amidon, Ph.D., Co-investigators: Lynda
Welage, Pharm.D., Jeffrey Barnett, M.D., 10/94-11/95.
General Clinical Research Center. “The Effect of Food and Gastric pH on the Oral Bioavailability of Itraconazole.”
Principal Investigator: Gordon Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Jeffrey Barnett, M.D.,
10/94-11/95.
Janssen Pharmaceutica Research Foundation- investigator initiated. “The Effect of Food and Gastric pH on the
Pharmacokinetics of Itraconazole.” Principal Investigator: Peggy Carver, Pharm.D., Co-investigators: Lynda
Welage, Pharm.D., Carol Kauffman, M.D., 5/94 -4/96, $60,640.
General Clinical Research Center “Intestinal Permeability of Ranitidine in Humans.” Principal Investigator: Gordon
Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Jeffrey Barnett, M.D., 5/94-6/95.
General Clinical Research Center. “Intestinal Permeability of Cimetidine in Humans.” Principal Investigator:
Gordon Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Jeffrey Barnett, M.D., 4/94-5/95
Burroughs Welcome. “Pilot Study on the Safety of Neuromuscular Blockade in the Intensive Care Unit (ICU).”
Principal Investigator: Lynda Welage, Pharm.D., 12/93-11/94, $1,590.
General Clinical Research Center. “The Effect of Viscosity on Gastric Emptying for Application to the Microgravity
Environment.” Principal Investigator: Gordon Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Jeffrey
Barnett, M.D., 9/93-9/94.
Glaxo, Inc. - investigator initiated. “National Survey of H2RA Selection Policies in Non-Federal Hospitals.”
Principal Investigator: Rosemary Berardi, Pharm.D., Co-investigators: Lynda Welage, Pharm.D., Duane Kirking,
Ph.D. 2/93-2/94, $24,524.
Pfizer/Roerig - investigator initiated. “Unrestricted Support To Study The Oral Bioavailability Of Azole Drugs in
HIV Patients.” Principal Investigator: Peggy Carver, Pharm.D., Co-investigators: Lynda Welage, Pharm.D., Carol
Kauffman, M.D., 5/93-4/95, $19,900.
General Clinical Research Center. “Absorption of Azole Agents in HIV-Infected Patients with Altered Gastric pH.”
Principal Investigator: Peggy Carver, Pharm.D., Co-investigators: Lynda Welage, Pharm.D., Carol Kauffman, M.D.,
5/93-6/93.
L. S. Welage - 14
RW Johnson. “Single Dose Pharmacokinetics and Safety of FK-037 in the Presence of Renal Dysfunction.”
Principal Investigator: David Smith, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Nancy Mason, Pharm.D.,
5/93-12/93, $147,375.
Food and Drug Administration. “Oral Drug Delivery and Bioavailability - AIDS.” Principal Investigator: Gordon
Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Jeffrey Barnett, M.D., 9/92- 9/95, $1,757,608.
General Clinical Research Center. “Intestinal Permeability of Piroxicam in Humans.” Principal Investigator:
Gordon Amidon, Ph.D., Co-investigators: Lynda Welage, Pharm.D., Jeffrey Barnett, M.D., 2/93-5/94.
Baxter - investigator initiated. “The Effect of Hemodialysis Using Cellulose Triacetate Dialyzers on Vancomycin
Pharmacokinetics.” Principal Investigator: Nancy Mason, Pharm.D., Co-investigator: Lynda Welage, Pharm.D.,
Richard Swartz, M.D. 12/92-12/93, $12,000.
Pfizer/Roerig - investigator initiated. Unrestricted support in the area of selective decontamination. Principal
Investigator: Lynda Welage, Pharm.D., Co-investigator: Robert Bartlett, M.D., 1/92 – 12/92, $65,997.
Upjohn Faculty Grant - investigator initiated. “Evaluation of the Utility of a Marker Substrate for Hepatic
Dysfunction and Drug Metabolism in Selected Critically Ill Populations.” Principal Investigator: Lynda Welage,
Pharm.D., 2/92-9/94, $25,000.
General Clinical Research Center. “Evaluation of Prothrombin Time Variability Over a 24-Hour Period.” Principal
Investigator: Barry Bleske, Pharm.D., Co-investigators: Lynda Welage, Pharm.D., Michael Shea, M.D., 5/92-5/94.
General Clinical Research Center. “The Influence of Dosage Form on the Pharmacokinetics and Pharmacodynamics
of Propranolol Enantiomers.” Principal Investigator: Gordon Amidon, Ph.D., Co-investigators: Lynda Welage,
Pharm.D., Barry Bleske, Pharm.D., Michael Shea, M.D., 4/91-4/92.
General Clinical Research Center. “Alterations in Gastric Acidity and Gastric Microbial Colonization in Patients
with Acquired Immunodeficiency Syndrome.” Co-Principal Investigators: Lynda Welage, Pharm.D., Peggy Carver,
Pharm.D., Co-investigator: Carol Kauffman, M.D., 2/91-10/93.
Pfizer/Roerig - investigator initiated. “Unrestricted Support in the Area of Gastric Acidity and AIDS.” Co-Principal
Investigators: Lynda Welage, Pharm.D., Peggy Carver, Pharm.D., 1/92 – 12/93, $12,000.
General Clinical Research Center. “Effects of Interdigestive Gastrointestinal pH and Motility on the Oral
Absorption of Cimetidine in Humans.” Principal Investigator: Gordon Amidon, Ph.D., Co-investigators: Lynda
Welage, Pharm.D., Jeffrey Barnett, M.D., 12/90-12/95.
Roche-Laboratories - investigator initiated. “The Influence of Cimetidine, Ranitidine and Famotidine on
Cardiac Function as Determined by Echocardiography in a Randomized Crossover Study.” Principal
Investigator: Barry Bleske, Pharm.D., Co-investigators: Lynda Welage, Pharm.D., Michael Shea, M.D., 10/9012/91, $12,000.
Upjohn Company. “Pharmacoeconomic Analyses, Safety and Pharmacokinetics of Cefmetazole Given by
Intravenous Push Injection in Pre-operative Surgical Prophylaxis.” Principal Investigator: Lynda Welage, Pharm.D.,
5/90 -12/91, $42,146.
General Clinical Research Center. “Comparison of the Effects of Immediate and Sustained Release Verapamil on
Propranolol Pharmacokinetics.” Principal Investigator: Barry Bleske, Pharm.D., Co-investigators: Lynda Welage,
Pharm.D., Michael Shea, M.D, 2/90-2/91.
Merck Sharp & Dohme. General Research Support, Principal Investigator: Lynda Welage, Pharm.D., $2,000.
Lederele Laboratories - investigator initiated. “Pharmacokinetics of Piperacillin in Pediatric Patients.” Principal
Investigator: Pamela Jacobson, Pharm.D, Co-investigator: Lynda Welage, Pharm.D. 1/90-12/95, $18,000.
L. S. Welage - 15
Rackham Faculty Grant. “An In-Vitro Evaluation of Bacterial Adherence and Migration on the Surface of
Nasogastric Tubes.” Principal Investigator: Lynda Welage, Pharm.D., 5/89-6/91, $9,130.
PUBLICATIONS
Research:
Miller JT, Welage LS, Kraft MD, Alaniz C. Does body weight impact the efficacy of vasopressin therapy in the
management of septic shock? J Crit Care. 2012 Jun;27(3):289-93. [PMID 21855282]
Bleske BE, Erickson SR, Fahoum S, Devarakonda KR, Welage LS, Koudmani M, Pantham N, Edwin SB,
Devarakonda S, Shea MJ, Martha S, Khalidi N. Cardiovascular risk among university students from developed and
developing nations. Open Cardiovasc Med J. 2011;5:117-22. [PMID 21673835]
Stout SM, Nielsen J, Bleske BE, Shea M, Brook R, Kerber K, Welage LS. The impact of paroxetine coadministration on stereospecific carvediolol pharmacokinetics. J Cardiovasc Pharmacol Ther 2010; 15(5):373-9.
[PMID 20705902]
Stout SM, Nielsen J, Welage LS, Shea M, Brook R, Kerber K, Bleske BE. Influence of metoprolol dosage release
formulation on the pharmacokinetic drug interaction with paroxetine. J Clin Pharmacol 2010; 51(3):389-96. [PMID
20400652]
Foster DR, Gonzales JP, Amidon GL, Welage LS. Intestinal dipeptide permeability is preserved during thermal
injury and cytokine treatment. JPEN. J Parenter Enteral Nutr. 2009; 33(5):520-8. [PMID 19443858]
Sweet B, Welage L, Johnston JP. Effect of a web-based continuing education program on pharmacist learning. Am
J Health Syst. Pharm. 2009; 66:1902-3 [PMID 19850780]
Alaniz C, Mohammad RA, Welage LS. Does continuous pantoprazole infusion combined with octreotide improve
the management of variceal hemorrhage? Pharmacotherapy. 2009;29:248-54.[PMIC 19249944]
Foster DR, Yee S, Bleske BE, Carver PL, Stetson PL, Shea MJ, Menon SS, Ramachandran C, Welage LS, Amidon
GL. Lack of interaction between peptidomimetic substrates captopril and cephradine in humans. J Clin Pharmacol
2009; 49:360-7. [PMID 19246733]
Foster DR, Landowski CP, Amidon GL, Welage LS. Interferon-γ increases expression of the oligopeptide
transporter, h-pept1, and dipeptide transport in cultured human intestinal monolayers. Pharmacologic Research.
2009; 59:215-20. [PMID 19084598]
Higaki K, Choe SY, Lohenberg R. Welage LS, Amidon Gl. Mechanistic understanding of time dependent
absorption based on gastric motor activity in humans. Eur J Pharm Biopharm 2008; 70:313-25.[PMID 18434110]
Daley RJ, Rebuck JA, Welage LS, Rogers F. Prevention of stress ulceration: current trends in critical care. Crit
Care Med 2004; 32(10): 2008-13. [PMID 15483408]
Neudeck BL, Foster DR, Li LY, Gonzales JP, Welage LS. The effect of thermal injury on transcellular permeability
and intestinal P-glycoprotein in rats. Burns 2003;29(8):803-9. [PMID 14636755]
Landowski CP, Sun D, Fostor DR, Menon SS, Ramachandran C, Barnett J, Welage LS, Amidon GL. Gene
expression in the human intestine and correlation with oral valacylovir pharmacokinetic parameters. J Pharmacol
Exp Ther 2003;306(2):778-86. [PMID 12750437]
L. S. Welage - 16
Mason NA, Neudeck BL, Welage LS, Patel JA, Swartz RD. Comparison of three vancomycin dosage regimens
during hemodiolysis with cellulose triacetate dialysis: post-dialysis versus intradialytic administration. Clin Nephol
2003;60(2):96-104. [PMID 12940611]
Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. Human jejunal permeability of cyclosporin
A: influence of surfactants on P-glycoprotein efflux Mechanisms. Pharm Res 2003;20(5):749-56. [PMID
12751630]
Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, Amidon GL.
Comparison of human duodenum and caco-2 gene expression profiles for 12,000 gene sequences tags and
correlation with permeability of 26 drugs. Pharm Res 2002;19(10):1400-1416. [PMID 12425456]
Takamatsu N, Welage LS, Hayashi Y, Yamamoto R, Barnett JL, Shah VP, Lesko LJ, Ramachandran C, Amidon
GL. variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in
humans: correlation with antral gastric motility. Eur J Pharm Biopharm 2002;53(1):37-47. [PMID 11777751]
Choe SY, Neudeck BL, Welage LS, Amidon GE, Barnett JL, Amidon GL. Novel method to assess gastric emptying
in humans: the pellet gastric emptying test. Euro J Pharm Sci 2001;14 (4):347-53. [PMID 11684410]
Takamatsu N, Kim ON, Welage LS, Idkaidek NM, Hayashi Y, Barnett J, Yamamoto R, Lipka E, Lennernas H,
Hussain A, Lesko L, Amidon GL. Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharm
Res 2001;18(6):742-744. [PMID 11474776]
Neudeck BL, Taddonio TE, Garner LW, Welage LS. Determination of fluoxetine and norfluoxetine concentrations
in cadaveric allograft skin. Pharmacotherapy 1998;18(4):851-855. [PMID 9692660]
Bleske BE, Welage LS, Kramer WG, Nicklas JM. Torsemide administration in patients with decompensated and
compensated congestive heart failure. J Clin Pharmacol 1998;38:708-14. [PMID 9725546]
Rhie JK, Hayashi Y, Frens J, Welage LS, Wald RJ, Barnett JL, Amidon GE, Putcha L, Amidon GL. The absorption
of drug markers from enteric coated pellets in relation to gastric motility and caloric viscous meals in humans.
Pharm Res 1998;15(2): 233-238. [PMID 9523309]
Takamatsu N, Welage LS, Liu DY, Lee PI, Hayashi Y, Rhie JK, Lennernas H, Barnett JL, Shah VP, Lesko L,
Amidon GL. Human intestinal permeability of piroxicam, propranolol, phenylalanine and PEG 400 determined by
jejunal perfusion. Pharm Res 1997;14(9):1127-1132. [PMID 9327437]
Welage LS, Mason NA, Hoffman EJ, Odeh RM, Dombrouski J, Patel JA, Swartz RD. Influence of cellulose
triacetate hemodialyzers on vancomycin pharmacokinetics. J Am Soc Neph 1995;6(4):1284-1290. [PMID 8589298]
Bleske BE, Welage LS, Warren EW, Brown MB, Shea MJ. Variation in prothrombin times and INR over a 24 hour
period in patients receiving warfarin. Pharmacotherapy 1995;15(6):709-712. [PMID 8602377]
Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA. Alterations in gastric acidity in patients with HIV
Infection. Clin Infect Dis 1995;21:1431-8. [PMID 8749628]
Ballow CH, Wels PB, Welage LS, Walczak P, Williams JS, Schentag JJ. A double-blind randomized comparison of
aztreonam plus clindamycin with tobramycin plus clindamycin in abdominal infections. Am J Ther 1995;2:1-5.
[PMID 11850680]
Timm EG, Welage LS, Walawander CA, Sayers JFB, Karpuik E, Davis TD, Grasela TH. Adverse drug reaction
reporting in a multi-center surveillance study. Ann Pharmacother 1995;29(3):240-245. [PMID 7606067]
Welage LS, Dunn-Kucharski VA, Berardi RR, Shea MJ, Dechert RE, Bleske BE. Comparative evaluation of the
hemodynamic effects of oral cimetidine, ranitidine and famotidine as determined by echocardiography.
Pharmacotherapy 1995;15(2):158-163. [PMID 7624262]
L. S. Welage - 17
Bleske BE, Welage LS, Rose S, Amidon GL, Shea MJ. The effect of dosage release formulations on the
pharmacokinetics of propranolol stereoisomers in humans. J Clin Pharmacol 1995;35:374-378. [PMID 7650226]
Conboy K, Welage LS, Walawander CA, Duffy LC, Welliver RC, Zielezyn MA, Raebel MA, DiPiro J, Grasela TG.
The incidence of sepsis syndrome and associated sequelae in a population of patients at high risk for gram negative
sepsis. Pharmacotherapy 1995;15(1):66-77. [PMID 7739948]
Welage L, Carver P, Welch K. Antibacterial activity of sucralfate versus aluminum chloride in simulated gastric
fluid. Eur J Clin Microbiol Infect Dis 1994;13(12):1046-1052. [PMID 7889966]
Paladino JA, Serrianne DJ, Rainstein MA, Przylucki JE, Welage LS, Collura ML, Schentag JJ.
Ampicillin/sulbactam versus cefoxitin for prophylaxis in high risk abdominal surgery patients. Pharmacotherapy
1994;14(6):734-739. [PMID 7885978]
Bleske BE, Welage LS, Touchette MA, Edwards DJ, Shea MJ. Evaluation of dosage release formulations on
inhibition of drug clearance: effect of sustained and immediate release verapamil on propranolol pharmacokinetic
parameters. Ther Drug Monit 1994;16:216-220. [PMID 8009573]
Welage LS, Walawander CA, Timm EG, Grasela TH. Risk factors for acute renal insufficiency in patients with
suspected or documented bacterial pneumonia. Ann Pharmacother 1994;28:515-522. [PMID 8038478]
Lebsuck ME, Nix D, Ryerson B, Toothaker R, Welage L, Norman AM, Schentag JJ, Sedman AJ. Effect of gastric
acidity on enoxacin absorption. Clin Pharmacol Ther 1992;52(3):252-6. [PMID 1526081]
Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB,
McCarthy M, Plouffe J, Russell JA, and the Xoma Study Group. A controlled clinical trial of ES murine monoclonal
IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991;266(8):1097-1102. [PMID
1865542]
Welage LS, Borin MT, Wilton JH, Hejmanowski LG, Wels PB, Schentag JJ. A comparative evaluation of the
pharmacokinetics of N-Methyl-Thiotetrazole (NMTT) following cefoperazone, cefotetan, and cefmetazole.
Antimicrobial Agents Chemother 1990;34(12):2369-2374. [PMID 2088192]
Grasela TH, Welage LS, Walawander CA, Timm EG, Thies P, Pelter M, Poirier T, Walters K. A nationwide survey
of initial antibiotic prescribing patterns and clinical outcomes in 1,822 patients with bacterial pneumonia. DICP
1990;24:1220-1225. [PMID 2089835]
Schentag JJ, Carter CA, Welage LS. The safety and acid suppressant properties of the H2 receptor antagonists in
critical care patients for the prevention of stress related mucosal damage. DICP 1989;23:536-539. [PMID 2573208]
Grasela TH, Walawander CA, Welage LS, Wing PE, Scarafoni DJ, Caldwell JW, Noquchi JK, and Schentag JJ.
Prospective surveillance of antibiotic associated coagulopathy in 970 patients. Pharmacotherapy 1989;9(3):158-164.
[PMID 2755867]
Gin AS, Stringer KA, Welage LS, Wilton JH and Matthews GE. The effect of verapamil on the pharmacokinetic
disposition of theophylline in cigarette smokers. J Clin Pharm 1989;29(8):728-832. [PMID 2778093]
Gutfeld MB, Welage LS, Walawander CA, Wilton JH, and Harrison NJ. The influence of cimetidine dosage
regimens on the disposition of theophylline. J Clin Pharm 1989;29:665-669. [PMID 2760260]
Welage LS, Hejmanowski LG, Wilton JH, Walawander C, Rigan D, Williams JS and Schentag JJ. Comparison of
N- Methyl-Thiotetrazole disposition in healthy volunteers following single intravenous dosages of and moxalactam,
cefoperazone and cefotetan. Antimicrobial Agents Chemother 1989;33(6):857-861. [PMID 2764537]
L. S. Welage - 18
DiPiro JT, Welage LS, Levin BA, Wing PE, Stanfield JA, Gaskill HV, Scarafoni DS, Schentag JJ, Bowden TA and
Williams JS. Single dose cefmetazole versus multiple dose cefoxitin for prophylaxis in abdominal surgery. J
Antimicrob Chemother 1989;23(Suppl D):71-77. [PMID 2722725]
Schentag JJ, Welage LS, Williams JS, Wilton JH, Adelman, MH, Rigan D and Grasela TH. Kinetics and action of
N- methylthiotetrazole in volunteers and patients. Am J Surg 1988;155(5A):40-44. [PMID 3163900]
Smith IL, Swanson DJ, Welage LS, DeAngelis C, Boudinot SA and Schentag JJ. Determination of cefmenoxime in
human serum by ion-pair reverse-phase high performance liquid chromatography. Anal Lett 1985;18(B9):10421180.
Welage LS, Schultz RW and Schentag JJ. Pharmacokinetics of ceftazidime in patients with renal insufficiency.
Antimicrobial Agents Chemother 1984;25:201-204. [PMID 6370127]
Book Chapters:
Welage LS, Wolfe MM. Pharmacologic principles for the gastroenterologist. In: Educational Review Manual in
Gastroenterology. 5rd edition. Benjamin S, Ed. Castle Connolly Graduate Medical Publishing, Ltd, New York, New
York, 2009.
Berardi R, Welage LS. Peptic Ulcer Disease. In: Pharmacotherapy. A pathophysiologic approach. DiPiro JT,
Talbert RL, Hayes PE, Yee GC and Posey LM, Eds. 7th Edition. Appleton & Lange. Norwalk, Connecticut, 2008.
Welage LS, Wolfe MM. Pharmacologic principles for the gastroenterologist. In: Educational Review Manual in
Gastroenterology. 4rd edition. Benjamin S, Ed. Castle Connolly Graduate Medical Publishing, Ltd, New York, New
York, 2006
Berardi R, Welage LS. Peptic ulcer disease. In: Pharmacotherapy. A Pathophysiologic Approach. DiPiro JT, Talbert
RL, Hayes PE, Yee GC and Posey LM, Eds. 6th Edition. Appleton & Lange. Norwalk, Connecticut, 2005.
Welage LS, Wolfe MM. Pharmacologic principles for the gastroenterologist. In: Educational Review Manual in
Gastroenterology. 3rd edition. Benjamin S, Ed. Castle Connolly Graduate Medical Publishing, Ltd, New York, New
York, 2004
Welage LS. Principles of pharmacology in the ICU. In: Handbook of Critical Care. Hall JB, Ed. Science Press Ltd.,
London, England, 2003.
Welage LS, Wolfe MM. Pharmacologic principles for the gastroenterologist. In: Educational Review Manual in
Gastroenterology. 2nd edition. Benjamin S, Ed. Castle Connolly Graduate Medical Publishing, Ltd, New York,
New York, 2002.
Foster DR, Welage LS. Burns. In: Book 6. Critical Care/Urgent Care. Pharmacotherapy Self Assessment Program
4th edition, Berch K, Dunsworth T, Fagan S, Hayney M, Meuller B, O’Donnell D, Schumock G, Tisdale J,
Thompson D, Witt D, Zarowitz B, eds. American College of Clinical Pharmacy., Kansas City, Missouri. 2002.
Welage LS. Disease and Oral Dosage Form Performance. In: Scientific Foundations for Regulating Drug Product
Quality. Amidon GL, Robinson JR, Williams RL, Eds. AAPS Press. Alexanderia, Virginia. 1997.
Williams DB, Welage LS. Gastroesophageal reflux. In: Pharmacotherapy. A Pathophysiologic Approach 3rd
edition. DiPiro JT, Talbert RL, Hayes PE, Yee GC and Posey LM, Eds. Appleton & Lange. Norwalk, Connecticut.
1996.
Welage LS. Chapter: Burns, In: Critical Care. Pharmacotherapy Self Assessment Program 2nd edition. Carter
BL, Angaran D, Lake K, Raebel M eds. American College of Clinical Pharmacy, Kansas City, Missouri. 1995.
L. S. Welage - 19
Woster PS, Guthrie SK, Ebert SL, and Welage LS. Criteria for use of chlordiazepoxide for the prophylaxis and/or
management of the alcohol withdrawal syndrome. Criteria for Drug Use Evaluation Volume 3. America Society of
Hospital Pharmacists' Special Projects Division. Bethesda, Maryland. 1992.
Welage LS. Surgical infections and antimicrobial prophylaxis. In: Clinical Pharmacy and Therapeutics, 5th
Edition, Hart L, Gourley DR, Herfindal ET, Eds. Williams and Wilkins, Philadelphia, Pennsylvania. 1992.
Welage LS. Surgical infections and antimicrobial prophylaxis cases. In: Clinical Pharmacy and Therapeutics 5th
Edition, Workbook. Hart L, Gourley DR, Herfindal ET, Eds. Williams and Wilkins, Philadelphia, Pennsylvania.
1992.
Welage LS. Gastroesophageal reflux. In: Pharmacotherapy. A Pathophysiologic Approach, DiPiro JT, Talbert
RL, Hayes PE, Yee GC and Posey LM, Eds. Appleton & Lange. Norwalk, Connecticut. 1993.
Schentag JJ, Ebbeling PL, Ziemniak JA, Welage LS and Bernard H. Comprehensive evaluation of the central
nervous system effects of cimetidine: a role for toxicokinetics, toxicodynamics and clinical studies in volunteers,
animal models and patients. In: Toxicokinetics and New Drug Development, Batra, Skelly and Yacobi, Eds.
Pergamon Press, Inc. Elmsford, New York. 1989.
Welage LS. Gastroesophageal reflux. In: Pharmacotherapy. A Pathophysiologic Approach, DiPiro JT, Talbert
RL, Hayes PE, Yee GC and Posey LM, Eds. Elseview Science Publishing Co. New York, New York. 1989.
Ziemniak, JS, Welage LS, Schentag JJ. Histamine H2-antagonists: cimetidine and ranitidine. In: Applied
Pharmacokinetics, WE Evans, JJ Schentag and WJ Jusko, Eds. Applied Therapeutics Inc. San Francisco, California.
1985.
Letters to the Editor:
Alaniz C, Mohammad RA, Welage LS. High-dose PPIs in paitents with variceal hemorrhage. Arch Intern Med
2010; 170:1698. [PMID 20937934]
Rebuck JA, Daley RJ, Welage LS. Devlin J, Welage LS. Caution and patient safety concerns should guide us- The
authors’ reply. Crit Care Med 2005, 33: 472.
The cost effectiveness of proton pump inhibitors for bleeding peptic ulcers: The unanswered questions. Letter to the
Editor. Crit Care Med 2004; 36(6):1415-16. [PMID 15187531]
Wolfe MM, Welage LS, Sachs G. Proton pump inhibitors. Letter to the Editor. Am J Gastroenterol
2001;96(12):3467-8. [PMID 11774990]
Review Articles:
Kaufman A, Roth PB, Larson RS, Ridenour N, Welage LS, Romero-Leggott V, Nkouaga C, Armitage K, McKinney
KL. Vision 2020 measures University of New Mexico’s success by health of its state. Am J Prev Med 2015;
48(1):108-15. [PMID: 25441236]
Parker RB, Ellingrod V, DiPiro JT, Bauman JL, Blouin RA, Welage LS. Preparing clinical pharmacy scientists for
careers in clinical/translational research: can we meet the challenge? AACP Research Affairs Committee
Commentary. Pharmacotherapy 2013;33(12):e337-46. [PMID: 24114730]
Janke KK, Seaba HH, Welage LS, Scott SA, Rabi SM, Kelley KA, Mason HL. Building a multi- institutional
community of practice to foster assessment. Am J Pharm Educ 2012; 76(4):58. [PMID:22611267]
Crismon ML, Albright FS, Canney DJ, Das NG, Mehanna AS, Welage LS, Wu-Pong S, Miller KW. The role of
dual- degree programs in colleges and schools of pharmacy: the report of the 2008-09 Research and Graduate
Affairs Committee. Am J Pharm Educ. 2009;73 Suppl:S6. [PMID 20221388]
L. S. Welage - 20
Erstad BL, Brophy GM, Martin SJ, Haas CE, Devlin JW, Welage LS, Dager WD. Key articles and guidelines
relative to intensive care unit pharmacology- 2009 update. Pharmacotherapy 2009;29:1228-69. [PMID 19792995]
Devlin JW, Welage, LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill: Part 2:
clinical efficacy, safety and economics. Ann Pharmacotherapy 2005; 39(11): 1844-51. [PMID 1620439]
Devlin JW, Welage, LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill: Part 1:
Pharmacology, pharmacodynamics and available formulations. Ann Pharmacotherapy 2005; 39(10):1667-77.
[PMID 16118266]
Welage LS. Overview of pharmacologic agents for acid suppression in critically ill patients. Am J Health-System
Pharmacy 2005;62 (10 Suppl 2): S4-10. [PMID 15905600]
Erstad BL. Martin SJ. Brophy GM. Haas CE. Jacobi J. Welage LS. Thomas MC. Key articles and guidelines relative
to intensive care unit pharmacology--2004. Pharmacotherapy. 2005; 25(4):585-610. [PMID 15977919]
McGuigan JE, Belafsky PC, Fromer L, McCarthy D, Nostrant T, Postma GN, Welage LS, Wolfe MM. Review
article: diagnosis and management of night-time reflux. Aliment Pharmacol Ther 2004; 20 (Suppl 9): 57-72. [PMID
15527465]
Welage LS. Pharmacologic properties of the proton pump inhibitors: comparing the agents. Pharmacotherapy,
2003; 23 (10 Pt 2):74S-80S. [PMID 14587961]
Welage LS. Pharmacologic features of proton pump inhibitors and their potential relevance to clinical practice.
Gastroenterol Clin North Am, 2003; 32 (3 Suppl):S25-35. [PMID 1455433]
Brunton S, Ehrenpreis ED, Mennie G, Tranmer P, Orr W, Shaker R, Welage LS. Night -time gastroesophageal
reflux: important diagnostic and management issues for primary care. Consensus Recommendations from an Expert
Panel. IAFP 2003;4(4):1-12.
Welage LS, Ellis J, Alaniz C. Gastrointestinal alterations in critically ill. Pharmacy Practice News 2003;7:46-51
Cohen H, Welage LS. Strategies to optimize drotrecogin alfa (activated) utilization: guidelines and therapeutic
controversies. Pharmacotherapy 2002;22:223S-235S. [PMID 12492229]
Welage LS, Kirking DM, Ascione FJ, Gaither CA. Understanding the scientific issues embedded in the generic
approval process. J Am Pharm Assoc 2001;41(6):856-67. [PMID 11765111]
Christensen TP, Kirking DM, Ascione FJ, Welage LS, Gaither CA. Drug product selection: legal issues. J Am
Pharm Assoc 2001;41(6):868-74. [PMID 11765112]
Gaither CA, Kirking DM, Ascione FJ, Welage LS. Consumer’s reviews on generic medications. J Am Pharm
Assoc 2001;41(5):729-36.
Kirking DM, Gaither CA, Ascione FJ, Welage LS. Pharmacist’s individual and organizational views in generic
medications. J Am Pharm Assoc 2001;41(5):723-8.
Kirking DM, Gaither CA, Ascione FJ, Welage LS. Physicians’ individual and organizational views on generic
medications. J. Am Pharm Assoc 2001;41(5):718-22.
Kirking DM, Ascione FJ, Gaither CA, Welage LS. Economics and structure of the generic pharmaceutical industry.
J Am Pharm Assoc 2001;41(4):578-84. [PMID 11486984]
Ascione FJ, Kirking DM, Gaither CA, Welage LS. Historical overview of generic medication policy. J Am Pharm
Assoc 2001;41(4):567-77. [PMID 11486983]
L. S. Welage - 21
Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole and rabeprazole in the treatment of
acid-related disorders. J Am Pharm Assoc 2000;40:52-62. [PMID 10665250]
Berardi R, Welage LS. Proton pump inhibitors in acid related diseases. Am J Health Syst Pharm 1998;55:2289-98.
[PMID 9825880]
Manzo J, Guerrero RM, Welage LS, Fichtl RE. Formulary evolution and the role of appropriate use guidelines.
Hospital Pharmacist Report. Supplement; December, 1996.
Welage LS, Berardi RR. Drug interactions with antiulcer agents: considerations in the treatment of acid peptic
disease. J Pharmacy Practice 1994;VII(4):177-195.
Berardi RR, Welage LS. Current status of gastric proton pump inhibitors in the treatment of acid-peptic disease. J
Pharmacy Practice 1994;VII(4):165-176.
Welage LS. Biotechnology and pharmaceutical care: pharmacy issues regarding monoclonal antiendotoxin
antibodies. J Michigan Pharmacist 1992;April:172-178.
Schentag JJ, Welage LS, Grasela TH, Adelman MH. Determinants of antibiotic-associated hypoprothrombinemia.
Pharmacotherapy 1987;7(3):80-86. [PMID 3306622]
Welage LS, Schentag JJ. Clinical and pharmacological considerations in the use of cimetidine in the elderly.
Geriatric Medicine Today 1983;2:33-41.
Continuing Education Monographs:
Birmingham MC, Welage LS. Adverse effects of antimicrobial agents used to treat gram-positive bacterial
infections. Medical Education Resources and Synergy Medical Communications. Continuing Education
Monograph. 2002.
CME Circle. “Progress toward disease resolution: have we improved the treatment of GERD and other acid-related
disorders?” Chairperson: Wolfe MM; Faculty: McCarthy DM, Sung JJY, Welage LS. Release date: September 5,
2001; Expiration: September 5, 2002.
http://www.medscape.com/CMECircle/Gastroenterology/2001/CME04/public/toc-CME04.html
Welage LS, Herrington A, Garnett W, Wolfe MM. Proton pump inhibitors in PUD and GERD. Power-Pak CE,
2001.
Erstad B, Garnett WR, Pisegna JR, Spirt MJ, Welage LS (eds). Reducing gastrointestinal complications: advances
in acid suppressant therapy. Continuing Education Monograph. June 2001.
American Association Pharmaceutical Association. New product bulletin - Aciphex
Keil R, Robinson M, Welage LS. (advisory board), 1999.
(Rabeprazole). Barone JA,
American Association Pharmaceutical Association. APhA Special Report: The use of proton pump inhibitors in
acid- peptic disorders. Horn JR, Keil R, Robinson M, Welage LS. (advisory board), 1999.
ABSTRACTS/SCIENTIFIC PRESENTATIONS
Nguyen TT, Welage LS, and Salama, NN. Evidence of concurrent genetic downregulation in mdrla and Bcrp under
acute inflammation. 27th Annual Meeting and Exposition of The American Association of Pharmaceutical Scientists
(AAPS), November 10-14, 2013, San Antonio, TX. (under review)
L. S. Welage - 22
Nguyen, TT, Welage LS, Salama NN. Genetic Downregulation of Mdrla In Acute Inflammation Such As Systemic
Inflammation Response Syndrome. St. Louis College of Pharmacy 4th annual student research symposium, April 6,
2013. St. Louis, MO [abstract] (poster presentation)
Salama NN, Welage, LS. Evidence of Genetic Downregualtion in the Breast Cancer Resistance Protein in Diseases
Characterized by Acute Inflammation such as Systemic Inflammatory Response Syndrome. 26th Annual Meeting
and Exposition of The American Association of Pharmaceutical Scientists (AAPS), October 14-18, 2012, Chicago,
IL. [abstract] (poster presentation)
Salama NN, Nielsen J, Patel JH, Welage LS. Disease associated changes in p-glycoprotein in acute inflammation.
American Association Pharmaceutical Scientists. Los Angeles, CA. November 2009 [abstract] (poster/oral
presentation)
Miller JT, Welage LS, Kraft MD. Does body weight impact the efficacy of vasopressin therapy in the management
of septic shock? Society of Critical Care Medicine Annual Meeting, January 31-February 3, 2009, Nashville, TN
[abstract] (poster presentation)
Salama NN, Nielsen J, Patel JH, Welage LS. Disease Associated Changes in P-glycoprotein in Acute Inflammation,
Michigan Institutes for Clinical and Health Research (MICH-R) Annual Clinical Research Symposium. October
31st, 2008, Ann Arbor, MI [abstract] poster presentation)
Salama NN, Nielsen J, Patel JH, Welage, LS. Decreased hepatic P-glycoprotein expression in endotoxin-induced
acute inflammation. Society of Critical Care Medicine Annual Meeting, Honolulu, HI, February 2008. Crit Care
Med 2007;35:A37 [abstract] (poster presentation)
Sweet BV, Welage LS. Effect of a web-based continuing education program on pharmacist learning. 42nd Annual
Meeting of American Society of Health System Pharmacists, Las Vegas, Nevada. December 2007. (poster
presentation)
Bardou M, Pham CQ, Barkun AN, Martel M, Welage LS. Proton pump inhibitors vs. histamine 2 receptor
antagonists for stress related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. 11th Annual
Meeting of the French Society of Pharmacology and Therapeutics (EPHAR). Fundamental and Clinical
Pharmacology 2007; 21: 34. [abstract]
Pham CQD, Barkun AN, Bardou M, Martel M, Welage LS. Proton pump inhibitors for stress ulcer prophylaxis in
critically ill patients: a meta-analysis. Digestive Disease Week, May 2007. Gastroenterology 2007; 132(4 Suppl 2):
A497. [abstract]
San Luis VA, Hollis IB, Kraft MD, DePestel DD, Streetman DS, Stein E, Teter CJ, Welage LS. Adverse
Serotonergic effects observed in patients receiving concomitant linezolid and serotonin reuptake inhibitors.
American College of Clinical Pharmacy Annual Meeting. Denver, Colorado. October 2007.
Mohammad R, Alaniz C, Welage L, Smigel J, Tripp B. Octreotide versus octreotide and continuous infusion
pantoprazole in the treatment of variceal hemorrhage. American College of Clinical Pharmacy Spring Practice and
Research Forum. Memphis,TN., April, 2007.
Welage LS, Nielsen JC, Patel JH, An MS, Bush AR. Effect of endotoxin on hepatic MDR1a gene expression in
rats. Society of Critical Care Medicine Annual Meeting, Jan 2007. Crit Care Med 2006; 34 (12 Suppl S): A32.
[abstract] (poster presentation)
Elfant AB, Lange SM, Doan QV, Welage LS, Brunton S, Lynn RB, Dubois RW. Nighttime GERD and more severe
GERD symptomatology are associated with greater work productivity loss. Digestive Disease Week. 2006.
Gastroenterology 2006; 130(4 Suppl 2):A27. [abstract] (poster presentation)
L. S. Welage - 23
Lange SM, Doan Q, Elfant AB, Welage LS, Brunton S, Lynn RB. Treating nighttime GERD reduces overall costs
more substantially than treating daytime GERD - a population based economic model. Digestive Disease Week.
2006. Gastroenterology 2006;130 (4 Suppl 2):A455. [abstract] (poster presentation)
Brinker, Kraus M, Dimo M, Kraft M, Welage L, Walker P, Wahl W. Evaluation of the economic impact of
postoperative ileus, American Society of Health System Pharmacists Annual Meeting. Orlando, Florida. December
2005 (poster presentation)
Streetman DS, Welage LS, Qian W, Smoyer WE. Lymphocyte p-glycoprotein expression and pump activity in
pediatric steroid responsive and steroid resistant nephrotic syndrome. J Am Soc Nephrol 2005;16:781 [abstract]
(poster presentation).
Butler SO, Nielsen JC, Alaniz C, Johnson K, Welage LS. Discordance of international classification of diseases, 9th
edition (ICD-9) coding for severe sepsis at university hospital. Poster presentation at the Society of Critical Care
Medicine 34thCritical Care Congress, Phoenix, AZ, Crit Care Med. 2004 (poster presentation)
Daley RJ, Rebuck JA, Welage LS, Rogers F. Prevention of stress ulceration: current trends in critical care. Society
of Critical Care Medicine Annual Meeting, Orlando, Florida. February 2004. Crit Care Med 2003;31(12):A85
[abstract] (poster presentation)
Gonzales JP, Foster DR, Welage LS. Alterations in drug absorption during critical illness: the role of the peptide
transporter. American College of Clinical Pharmacy Annual Meeting, Atlanta, Georgia, November 2003 (oral
presentation)
Taber S, Welage LS, Leady M, Streetman DS. Pharmacogenomics and Adverse Drug Reactions with
Cardiovascular Medications. American College of Clinical Pharmacy Annual Meeting, Atlanta, Georgia, November
2003. Pharmacotherapy 2003;23(10):1358 [abstract] (poster presentation)
Menon SS, Ramachandran C, Foster DR, Welage LW, Barnett JL, Amidon GL. Oral drug delivery of prodrugs and
carrier-mediated transport: mechanistic modeling approaches to describe the improved oral absorption of the
acyclovir prodrug, valacyclovir, in humans. University of Michigan, United States of American; 30th Annual
Meeting and Exposition of the Controlled Release Society, Glasgow, Scotland, July 2003. (oral presentation)
Foster DR, Landowski CP, Streetman DS, Sun D, Amidon GL, Welage LS. Alterations in the expression of key
intestinal transporters and metabolic enzymes in thermally injured rats. American College of Clinical Pharmacy,
Palm Springs, California. April 2003. Pharmacotherapy 2003;23:394. [abstract] (poster presentation)
Landowski CP, Neudeck BL, Foster DR, Gonzales JP, Sun D, Amidon GL, Welage LS. Alterations in cephalexin
transport and PEPT1 expression following thermal injury in rats. Molecular Biopharmaceutics, Honolulu,
Hawaii. January 2003. (poster presentation)
Foster DR, Gonzales JP, Landowski CP, Welage LS. Peptide permeability is preserved in cytokine treated caco2
cells. Society of Critical Care Medicine Annual Meeting. San Antonio, Texas. January, 2003. Crit Care Med
2003:31(suppl):A148. [abstract] (poster presentation)
Foster DR, Landowski CP, Welage LS. Interferon gamma increases dipeptide transport via increased expression of
the oligopeptide transporter in cultured intestinal monoloyers. American College of Clinical Pharmacy Annual
Meeting. Albuquerque, New Mexico. October 2002. Pharmacotherapy 2002; 10:1334. [abstract] (poster
presentation)
Welage LS, Karlstadt RG, Burton MS, Lynn RB. Pharmacokinetic comparison of five proton pump inhibitors.
American College of Clinical Pharmacy Annual Meeting, 2002. Pharmacotherapy 2002;22(10):1366 [abstract]
(poster presentation)
L. S. Welage - 24
Welage LS, Karlstadt RG, Burton MS, Lynn RB. Pharmacokinetic Comparison of Five Proton Pump Inhibitors.
Digestive Diseases Week. San Francisco, California. May 2002. Gastroenterology 2002;122(4 Suppl 1):A202.
[abstract] (poster presentation)
Landowski CP, Sun D, Menon SS, Ramachandran C, Barnett JL, Foster DL, Welage LS, Amidon GL. Gene
expression in the human intestine and correlation with oral valacylovir pharmacokinetic parameters. American
Pharmaceutical Scientists Annual Meeting. Toronto, Canada. November 2002. http://www.aapspharmaceutica.com/
search/abstract_view.asp?id=5790&ct=02Abstracts [abstract] (poster presentation)
Menon SS, Ramachandran R, Foster D, Welage LS, Barnett JL, Amidon GL. Time-dependent oral drug absorption
models: a mechanistic approach for valacyclovir. American Pharmaceutical Scientists Annual Meeting. Toronto,
Canada. November 2002. http://www.aapspharmaceutica.com/search/abstract_view.asp?id=5905&ct=02Abstracts
[abstract] (poster presentation)
Foster Dr, Sun D, Welage LS, Barnett JL, Landowski D, Fleisher D, Lee KD, Amidon GL. Variability in the
expression of key transporters and metabolic enzymes in human intestine. American College of Clinical Pharmacy
Spring Forum. Savannah, Georgia. April 2002. Pharmacotherapy 2002;22(3):410.[abstract] (poster presentation)
Foster DR, Tazuke Y, Welage LS. Interferon-gamma increases permeability to peptides in cultured human
intestinal monolayers. Society of Critical Care Medicine, Annual Meeting. San Diego, California. January 2002.
Critical Care Medicine 2002: 29 (Suppl): A91 [abstract] (poster presentation)
Tsai C. Streetman DS, Leady M, Welage LS. Pharmacodynamics and adverse drug events in cardovascular erug
therapy. American Society of Health-System Pharmacists Midear Clinical Meeting. New Orleans, Louisiana.
December 2001. (poster presentation)
Menon SS, Choe SY, Welage LS, Amidon GL. Time dependent drug absorption models: a mechanistic approach.
American Pharmaceutical Scientists Annual Meeting. Denver, Colorado. October 2001. AAPS PharmSci 2001
Supplement 3(4). available from http://www.aapspharmaceutica.com/scientificjournals/pharmsci/am-abstracts/2001
[abstract] (poster presentation)
Sun D, Lennernas H, Welage L, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, Amidon GL. In vivo/in
vitro intestinal drug permeability correlations of intestinal transporter expression. American Pharmaceutical
Scientists Annual Meeting. Denver, Colorado. October 2001. AAPS PharmSci 2001; Supplement 3(4). Awarded the
2001 CRS Cygnus Graduate Student Award for Outstanding Work in Drug Delivery. available from
http://www.aapspharmaceutica.com/scientificjournals/pharmsci/am-abstracts/2001. [abstract] (poster presentation)
Gonzales JP, Foster DR, Welage LS. Dipeptide transport following thermal injury. American College of Clinical
Pharmacy, Annual Meeting. Tampa, Florida. October 2001. Pharmacotherapy 2001; 21:1265 [abstract](poster
presentation)
Edmond M, McCLish D, Massie T, Wiblin R, Kauffman C, Welage L, Goff D, Rex J, Schuster M, Wenzel R. Risk
factors for nosocomial candidemia among patients in eight surgical intensive care units. Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), 2001. Abstracts of the Interscience Conference on
Antimicrobial Agents and Chemotherapy 2001;41:435 [abstract](poster presentation)
Sun D, Landowski C, Welage L, Foster D, Hsu CP, Higaki K, Fleisher D, Amidon GL. Implications of intestinal
transporters expression and in vitro and in vivo intestinal drug permeability correlation. Controlled Release Society
Annual Meeting. San Diego, California. June 2001. (oral presentation)
Neudeck BL, Gonzales JP, Klein RD, Wang SC, Li LY, Welage LS. Preservation of intestinal transcellular drug
transport and P-glycoprotein following thermal injury in rats despite alterations in intestinal cytokines. American
College of Clinical Pharmacy Annual Meeting. Kansas City, Missouri. November 1999. Pharmacotherapy
1999;19:1198. [abstract] (poster presentation)
L. S. Welage - 25
Mason NA, Welage LS, Kukusckin T, Shimp LA. Enhancing clinical skills through computerized medication
history interview module. American Society of Health System Pharmacists Midyear Meeting. Orlando, Florida.
December 1999. (poster presentation)
Mason NA, Ippel MJ, Sergay A, Welage LS. Evaluation of a case-based computer module to teach principles of
therapeutic drug monitoring. American Association Colleges of Pharmacy Annual Meeting. Boston, Massachusetts.
July 1999. (poster presentation)
Lee DC, Belden TL, Erickson ST, Samuels KM, Ascione FJ, Welage LS. Evaluation of pharmacy students’ and
residents’ clinical interventions on a critical care rotation. International Congress on Clinical Pharmacy. Orlando,
Florida. April 1999. Pharmacotherapy 1999;19(4):512. [abstract] (poster presentation)
Neudeck BL, Klein RD, Gonzales JP, Wang SC, Welage LS. Alterations in intestinal carrier mediated transport
following thermal injury in rats and the potential role of luminal cytokines. Society of Critical Care Medicine 28th
Educational and Scientific Symposium. San Francisco, California. January 1999. Crit Care Med 1999;27:A49.
[abstract] (poster presentation)
Welage LS, Gordon GL, Rhie J, Neudeck BL, Choe S. A noninvasive test for gastric emptying and intestinal
absorption. First Biennial Space Biomedical Investigators’ Workshop. Sponsored by the National Aeronautics and
Space Administration, and the Universities Space Research Association Division of Space Life Sciences. League
City, Texas. January 1999. (oral presentation)
Mason NA, Welage LS, Kukuschkin T. Computer simulated case studies to enhance clinical skills. American
Society of Health System Pharmacists Midyear Meeting. Las Vegas, Nevada, December 1998. (poster presentation)
Johnson LB, Welage LS, Young EW, Kauffman CA. Urine fluconazole (FLU) concentrations in patients with severe
renal insufficiency. Infectious Diseases Society of America 36th Annual Meeting. Denver, Colorado. November
1998. (poster presentation)
Choe SY, Neudeck B, Barnett J, Welage LS, Amidon GL. Validation of the size differentiated pellet gastric
emptying test (PGET) in human under different gastric conditions. American Association of Pharmaceutical
Scientists. San Diego, California. November 1998. Pharm Sci 1998; Supplement 1(1):489. [abstract] (poster
presentation)
Chui YY, Neudeck BL, Welage LS, Barnett J, Watkins PB, Lipka E, Amidon GL. Intestinal permeability of
cyclosporine A (CsA) in humans. American Association of Pharmaceutical Scientists. San Diego, California.
November 1998. Pharm Sci 1998;Supplement 1(1):448. [abstract] (poster presentation)
Reichert MG, Neudeck BL, Welage LS. Critical appraisal of serum concentration monitoring of single daily
dose aminoglycoside therapy in critically ill patients. American College of Clinical Pharmacy. Cincinnati, Ohio.
November 1998. Pharmacotherapy 1998;18:1144. [abstract] (oral presentation)
Mason NA, Neudeck BL, Elhasan NS, Wong A, Welage LS. Comparison of three vancomycin dosage regimens
during hemodialysis with cellulose triacetate dialyzers: post-dialysis vs. intradialytic administration. American
College of Clinical Pharmacy. Cinicinnati, Ohio. November 1998. Pharmacotherapy 1998;18:1152. [abstract]
(poster presentation)
Neudeck BL, Bleske BE, Rice TL, Hsu M, Taheri P, Rodriguez JL, Welage LS. Xanthine Oxidase, NAcetyltransferase-2, and P4501A2 activity in trauma patients as compared to healthy volunteers: use of caffeine as a
marker substrate. American College of Clinical Pharmacy. Phoenix, Arizona. November 1997. Pharmacotherapy
1997;17:1085-6. [abstract] (poster presentation)
Neudeck BL, Taddonio T, Garner WL, Welage LS. Determination of fluoxetine (Prozac) and norfluoxetine
concentrations in cadaveric allograt skin - a case report. American Association of Tissue Banks 21st Annual
Meeting. San Diego, California. August 1997. (oral presentation)
L. S. Welage - 26
Bleske BE, Welage LS, Kramer WG, Nicklas JM. Torsemide pharmacokinetics in patient with decompensated and
compensated congestive heart failure. American College of Clinical Pharmacy, Practice and Research Forum.
Panama City, Florida. April 1997. Pharmacotherapy 1998;17:184. [abstract] (poster presentation)
Welage LS, Neudeck BL, Iteld L, Bleske BE, Rice TL, Rhie J, Hus M. Dechert R, Taheri P, Rodriguez J.
Evaluation of the pharmacokinetics of caffeine in trauma patients as compared to health volunteers - a pilot study.
American College of Clinical Pharmacy, Spring Practice and Research Forum. Panama City, Florida. April 1997.
Pharmacotherapy 1997; 17:186. [abstract] (poster presentation)
Hsu MCP, Welage LS, Amidon GL. Validation of a modified HPLC method for quantification of caffeine
metabolites in human urine. Tenth Annual American Association of Pharmaceutical Scientists. Seattle,
Washington. October 1996. Pharm Res 1996;13:S36. [abstract] (poster presentation)
Rhie JK, Hayashi Y, Welage L, Wald RJ, Barnett JL, Amidon GE, Putcha L, Amidon GL. Size differentiated
gastric emptying assessment in humans with the non-invasive pellet gastric emptying test. Tenth Annual American
Association of Pharmaceutical Scientists. Seattle, Washington. October 1996. Pharm Res 1996;13:S283. [abstract]
(poster presentation)
Carver PL, Welage LS, Kauffman CA. The effect of food and gastric pH on the oral bioavailability of intraconazole
in HIV+ patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract
#A031. New Orleans, Louisana. October 1996. Abstracts of the Interscience Conference on Antimicrobial Agents
and Chemotherapy 1996;36(0):6. [abstract] (poster presentation)
Rhie JK, Hayashi Y, Welage LS, Barnett JL, Wald RJ, Amidon GE, Putcha L, Amidon GL. Evaluation of a novel
non-invasive method to assess size differentiated gastric emptying in humans. Ninth Annual American Association
of Pharmaceutical Scientists. Miami Beach, Florida. November 1995. Pharm Res 1995;12:S299. [abstract] (poster
presentation)
Kim ON, Yamamoto R, Welage LS, Lesko LJ, Amidon GL. Correlation between rat, dog, and human small
intestinal permeabilities of ranitidine. Ninth Annual American Association of Pharmaceutical Scientists. Miami
Beach, Florida. November 1995. Pharm Res 1995;12:S298. [abstract] (poster presentation)
Takamatsu N, Yamamoto R, Hayashi Y, Welage LS, Barnett J, Lesko L, Amidon GL. Effect of gastrointestingal pH
and motility on the oral absorption of cimetidine in humans. Ninth Annual American Association of Pharmaceutical
Scientists. Miami Beach, Florida. November 1995. Pharm Res 1995;12:S422. [abstract] (poster presentation)
Takamatsu N, Welage LS, Hayashi Y, Loi DY, Barnett J, Lennernas H, Lesko L, Amidon GL. Intestinal
permeability of cimetidine in humans. Ninth Annual American Association of Pharmaceutical Scientists. Miami
Beach, Florida. November 1995. Pharm Res 1995; 12:S299. [abstract] (poster presentation)
Carver PL, Kauffman CA, Welage LS. Altered gastric acidity and absorption of azole antifungal agents in HIVinfected patients. Trends in Invasive Fungal Infections 3. Brussels, Belgium. September 1995. (poster presentation)
Welage LS, Takamatsu N, Lennernas H, Amidon GL. Assessment of the intestinal permeability of drugs with
different transport routes of absorptions using a novel technique. American College of Clinical Pharmacy, Winter
Practice and Research Forum. Orlando, Florida. February 1995. Pharmacotherapy 1995;15(1):111. [abstract}
(poster presentation)
Welage LS, Warren EW, Shea MJ, Bleske BE. Diurnal variation in prothrombin times and INR. American College
of Clinical Pharmacy, Winter Practice and Research Forum. Orlando, Florida. February 1995. Pharmacotherapy
1995;15(1):109. [abstract] (poster presentation)
Frens JE, Rhie JK, Hayashi Y, Welage LS, Amidon GL. Determination of size differentiated gastric emptying
based on drug levels in plasma. American Society of Health System Pharmacists Midyear Clinical Meeting, Student
Poster Session. Miami Beach, Florida. December 1994. (poster presentation)
L. S. Welage - 27
McCreadie S, Takamatsu N, Welage LS, Amidon GL. Intestinal permeability of piroxicam in healthy volunteers.
American Society of Health System Pharmacists Midyear Clinical Meeting, Student Poster Session. Miami Beach,
Florida. December 1994. (poster presentation)
Takamatsu N, Lennernas H, Welage LS, Amidon GL. Intestinal permeability of piroxicam in humans. Eighth
Annual American Association of Pharmaceutical Scientists. San Diego, California. November 1994.
Pharmaceutical Research 1994;11(10 Suppl):S447. [abstract] (poster presentation)
Rhie JK, Hayashi Y, Welage LS, Barnett JL, Wald RJ, Amidon GE, Putcha L, Amidon GL. The Effect of meal
viscosity on the gastric emptying of 0.71 mm caffeine and 3.6 mm acetaminophen enteric coated pellets in humans.
Eighth Annual American Association of Pharmaceutical Scientists. San Diego, California. November 1994.
Pharmaceutical Research 1994;11(10 Suppl):S303. [abstract] (poster presentation).
Welage LS, Walawander CA, Conboy K, Raebel M, DiPiro J, Grasela TH. Evaluation of the influence of antibiotic
prescribing patterns on patient outcomes in a population of patients at high risk for gram negative sepsis. American
College of Clinical Pharmacy Annual Meeting. St. Louis, Missouri. August 1994. Pharmacotherapy
1994;14(3):362. [abstract] (oral presentation)
Welage LS, Walawander CA, Conboy K, Raebel M, DiPiro J, Grasela TH. Evaluation of the time sequence of the
sepsis continuum: time to sepsis syndrome, refractory shock, sepsis associated organ dysfunction and mortality in a
population of patients at high risk for gram negative sepsis. American College of Clinical Pharmacy Annual
Meeting. St. Louis, Missouri. August 1994. Pharmacotherapy 1994;14(3):365. [abstract] (poster presentation)
Rhie JK, Hayashi Y, Welage LS, Barnett JL, Wald RJ, Amidon GE, Putcha L, Amidon GL. The relationship
between gastric motility and plasma level profiles of enteric coated caffeine and acetaminophen pellets in humans.
26th Annual Pharmaceutics Graduate Student Research Meeting. Omaha, Nebraska. June 1994. (oral presentation)
Welage LS, Carver PL. Antibacterial Activity of Sucralfate (SUC) Versus aluminum chloride (AL) in simulated
gastric fluid (SGF). NATO Advanced Study Institute in Bioinorganic Chemistry. Rhodes, Greece. June 1994.
(poster presentation)
Dombrouski J, Mason N, Welage L, Hoffman E, Swartz R, Boyer C, Odeh R. The effect of hemodialysis with
cellulose triacetate (CT) dialyzers on vancomycin pharmacokinetics. American Nephrology Nurses Association.
Dallas, Texas. June 1994. (poster presentation)
Woster PS, Welage LS, Guthrie SK, Rawlings SL. Evaluation of the prophylactic use of chlordiazepoxide for
alcohol withdrawal syndrome. American Society of Health System Pharmacists Annual Meeting. Reno, Nevada.
June 1994. (poster presentation)
Conboy K, Welage LS, Grasela TH, Walawander CA. Applying the updated definitions for sepsis in a population of
patients at high risk for gram negative sepsis. Society Critical Care Medicine Annual Meeting. Orlando, Florida.
February 1994. Critical Care Medicine 1994;22(1):A14. [abstract] (poster presentation)
Mitrzyk B, Rice T, Bleske B, Welage LS. Pharmacokinetics of caffeine in trauma patients. Great Lakes Residency
Conference. April 1993. (oral presentation)
Welage LS, Shea MJ, Amidon GL, Bleske BE. The influence of dosage forms on the pharmacokinetics of R and S
propranolol. American College of Clinical Pharmacy Winter Practice and Research Forum. San Diego, California.
February 1994. Pharmacotherapy 1993;13(6):683-4. [abstract] (poster presentation)
Mason NA, Welage LS, Hoffman EJ, Odeh RM, Dombrouski JM, Swartz RD. The influence of hemodialysis with
the cellulose triacetate (CT) dialyzers on the pharmacokinetics of vancomycin. American College of Clinical
Pharmacy Winter Practice and Research Forum. San Diego, California. February 1994. Pharmacotherapy
1993;13(6):680. [abstract] (poster presentation)
L. S. Welage - 28
Carver PC, Welage LS, Revankar S, Jorgensen K, Pierson C, Welch K, Kauffman C. Alterations in gastric pH
microbial colonization in HIV + patients. 33rd ICAAC. American Society for Microbiology. Washington, DC.
October 1993. Program and Abstracts for the Interscience Conference on Antimicrobial Agents and Chemotherapy
1993;33(0):429. [abstract] (poster presentation)
Paladino JA, Serrianne DJ, Rainstein MA, Przylucki JE, Welage LS, Collura ML, Schentag JJ.
Ampicillin/sulbactam vs. cefoxitin for prophylaxis in high-risk abdominal surgery patients. American College of
Clinical Pharmacy Annual Meeting, Reno, Nevada. August 1993. Pharmacotherapy 1993;13(3):283. [abstract]
(poster presentation)
Carver PC, Welage LS. Bacterial adherence to the surface of nasogastric tubes (NGT) in stimulated gastric fluid
(SGF). American College of Clinical Pharmacy Annual Meeting. Reno, Nevada. August 1993. Pharmacotherapy
1993;13(3):284. [abstract] (poster presentation)
Welage LS, Carver PC. Antibacterial activity of sucralfate (SUC) versus aluminum chloride (AL) in simulated
gastric fluid (SGF). American College of Clinical Pharmacy Annual Meeting. Reno, Nevada. August 1993.
Pharmacotherapy 1993;13(3):276. [abstract] (poster presentation)
Welage LS. An evaluation of the comparative hemodynamic effects of cimetidine, ranitidine, famotidine vs. placebo
as determined by echocardiography. Clinical Faculty Research Seminar, University of Michigan College of
Pharmacy. Ann Arbor, Michigan. October 1992. (oral presentation)
Welage LS. A series of studies evaluating the potential influence of environmental factors or drugs on bacterial
growth in gastric fluid. Merck Health Science Associate Research Conference. Philadelphia, Pennsylvania. October
1992. (oral presentation)
Bleske BE, Welage LS, Touchette MA, Edwards DJ, Rodman D, Shea MJ. Comparison of the effect of immediate
and sustained release verapamil on the pharmacokinetic parameters of propranolol. American College of Clinical
Pharmacy Winter Practice and Research Forum. Phoenix, Arizona. February 1992. Pharmacotherapy
1991;11(6):37. [abstract] (poster presentation)
Dunn-Kucharski, VA, Welage LS, Berardi RR, Shea MJ, Bleske BE. Comparative evaluation of the hemodynamic
effects of cimetidine, ranitidine and famotidine as determined by echocardiography. American College of Clinical
Pharmacy Winter Practice and Research Forum. Phoenix, Arizona. February 1992. Pharmacotherapy
1991;11(6):36. [abstract] (poster presentation)
Carver PL, Welage LS. An in vitro study to assess the effect of pH on the growth of bacteria in simulated gastric
fluid. American College of Clinical Pharmacy Winter Practice and Research Forum. Fort Lauderdale, Florida.
February 1991. Pharmacotherapy 1991;11(1):102. [abstract] (poster presentation)
Welage LS, Walawander CK, Grasela TH. A multicenter survey of risk factors for nephrotoxicity in patients with
bacterial pneumonia. American Society for Clinical Pharmacology and Therapeutics Annual Meeting. San
Antonio, Texas. March 1992. Clin Pharmacol Ther 1991;49(2):150. [abstract] (poster presentation)
Welage LS. Anti-ulcer therapy as a risk factor for nosocomial pneumonia. Alumni Society Board of Governors,
College of Pharmacy, University of Michigan. Ann Arbor, Michigan. October 1990. (oral presentation)
Welage LS. A comparative evaluation of the production of N-Methyl-Thiotetrazole (NMTT) among
cephalosporins.” Research Seminar. Colleges of Pharmacy and Allied Health Professions. Wayne State University.
Detroit, Michigan. April 1989. (oral presentations)
LeBlanc KL, Welage LS, Carver PL. Evaluation of an in vitro interaction of norfloxacin with sucralfate or
aluminum. Fifth Annual Great Lakes Residency Conference. Indianapolis, Indiana. April 1990. (oral presentation)
L. S. Welage - 29
Brown CK, Carver PL, Welage LS. An in vitro study to assess the effects of pH and volume on bacterial growth in
simulated gastric fluid. Fifth Annual Great Lakes Residency Conference. Indianapolis, Indiana. April 1990. (oral
presentation)
Welage LS, Wilton JH, Schentag JJ, Wels PB, Borin MT. A comparative evaluation of the production of N-MethylThio-Tetrazole (NMTT) following cefoperazone (CPZ), cefotetan (CFT) and cefmetazole (CMZ). American
College of Clinical Pharmacy Annual Meeting. Kansas City, Missouri. August 1989. Pharmacotherapy
1989;9(3):189. [abstract] (poster presentation)
Welage LS. A comparative evaluation of NMTT following cefoperazone, cefotetan, and cefmetazole. College of
Pharmacy, The University of Michigan. Ann Arbor, Michigan. March 1989. (oral presentation)
Timm EG, Grasela TH, Welage LS. Detection of adverse drug reactions utilizing a nationwide network of clinical
pharmacists. American Society of Health System Pharmacists Midyear Clinical Meeting. Dallas, Texas. December
1988. (poster presentation)
Grasela TH, Timm EG, Welage LS. A nationwide survey of antibiotic utilization in bacterial pneumonia.
Twenty- Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, California.
May 1988. (poster presentation)
Grasela TH, Welage LS, Schentag JJ. A nationwide survey of antibiotic associated coagulopathy in patients.
American College of Clinical Pharmacy Annual Meeting. Philadelphia, Pennsylvania. July1988. Pharmacotherapy
1988;8(2):28A. [abstract] (poster presentation)
Welage LS, Wilton JH, Grasela TH, Schentag JJ and Rigan DP. A comparative evaluation of the pharmacokinetics
of N-Methyl-Thio-Tetrazole following cefoperazone, moxalactam, and cefotetan. American College of Clinical
Pharmacy Annual Meeting. Philadelphia, Pennsylvania. July 1988. Pharmacotherapy 1988;8(2):29A. [abstract]
(oral presentation)
Gutfeld MB, Welage LS, Walawander CA, and Harrison NJ. The influence of intravenous cimetidine dosing
regimens on the disposition of theophylline. American College of Clinical Pharmacy Annual Meeting. Philadelphia,
Pennsylvania. July 1988. Pharmacotherapy 1988;8(2):95A. [abstract] (poster presentation)
Paladino JA, Welage LS, Cumbo TJ and Schentag JJ. Cost comparison of oral ciprofloxacin vs. intravenous
antibiotics in a randomized clinical trial. American College of Clinical Pharmacy Annual Meeting. Philadelphia,
Pennsylvania. July 1988. Pharmacotherapy 1988;8(2):153A. [abstract] (poster presentation)
Schentag JJ, Simons GW, Windsale NE, Wels PB, Welage LS. Randomized comparison of aztreonam plus
clindamycin with tobramycin plus clindamycin for treatment of abdominal sepsis. 14th International Congress of
Chemotherapy. May 1988. (poster presentation)
Welage LS, Wing PE, Schentag JJ, Williams JS, Root JK and Berlin RG. An evaluation of intravenous famotidine
versus cimetidine therapy in the critically ill. Digestive Disease Week. May 1988. Gastroenterology
1988;94(5):A491. [abstract] (poster presentation)
Welage LS, Grasela TH, Thomas RW, Wing PE and Mueller GA. The concentration effect relationship of
nizatidine on stimulated gastric acid secretion. American Society of Clinical Pharmacology and Therapeutics.
Orlando, Florida. March 1987. Clin Pharmacol Ther 1987;41(2):168. [abstract] (poster presentation)
Grasela TH, Welage LS and Adelman MH. Population analysis of nizatidine concentration effect data. American
Society of Clinical Pharmacology and Therapeutics. Orlando, Florida. March 1987. Clin Pharmacol Ther
1987;41(2):167. [abstract] (poster presentation)
Schentag JJ, Simons GW, Windsale NE, Wels PB, Welage LS. Randomized comparison of aztreonam plus
clindamycin with tobramycin plus clindamycin for treatment of abdominal sepsis. 14th International Congress of
Chemotherapy. May 1988. (poster presentation)
L. S. Welage - 30
Welage LS, Wing PE, Thomas RW and Mueller GA. The effect of intravenous nizatidine on stimulated gastric acid
secretion. Proceedings of the American College Clinical Pharmacology Meeting. Philadelphia, Pennsylvania.
October 1986. J Clin Pharmacol 1986;26:541. [abstract] (poster presentation)
EDUCATIONAL PRESENTATIONS
Visiting Professorships:



University of Kalamoon, Syria May 2007
University of Wisconsin School of Pharmacy. August 2003.
University of Georgia, Medical College of Georgia. March 2002.
Invited Local and State Presentations:
(presented to pharmacists unless otherwise stated)
“Making the Most of the Mentor-Mentee Relationship.” University of New Mexico Department of Pathology.
Program presented to faculty, July 2016.
“Making the Most of the Mentor-Mentee Relationship.” University of New Mexico Health Science Center. Program
presented to University of New Mexico faculty as part of HSC faculty orientation, August 2013, 2014.
“Future of Healthcare and Education”. New Mexico Society of Health System Pharmacists, October 2012.
“Optimizing and Adaptive Clinical Trials- Panel Discussion.” MICHBIOS. Lansing, Michigan. September 2007.
“Mentoring and Career Development in Research.” MICHR Clinical Research Introductory Workshop. University
of Michigan. Ann Arbor, Michigan. November 2007.
“Budgeting the Clinical Research Study.” Multidisciplinary Clinical in Research Training Summer Seminar
Series. University of Michigan. Ann Arbor, Michigan. July 2007
“Data Management.” K30 Introductory Clinical Research Workshop. University of Michigan. Ann Arbor,
Michigan. September 2006.
“Optimizing Acid Suppressant Therapy in the Hospital Setting: Maximizing Appropriate Use of Proton Pump
Inhibitors” Program presented to Physicians, Nurses and Pharmacists in Grand Rapids, Ann Arbor and Flint,
Michigan. June 2005.
“Appropriate Use of Acid Suppressant Therapy.” East Lansing, Michigan. April 2005.
“Overview of the Drug Development Process.” Clinical Advancement for Clinical Research and General Clinical
Research Seminar Series. University of Michigan. Ann Arbor, Michigan. April 2005.
“Management of GERD.” American Health Resources, Pharmacy CE program. West Bloomfield, Michigan. August
2004.
“Acid Suppression in the Hospital Setting.” Western Michigan Society of Hospital Pharmacists, Grand
Rapids, Michigan. May 2004.
“Controversies in the Management of Upper Gastrointestinal Bleeding.” Pharmacy CE Program, Novi, Michigan.
May 2004.
“Online Pharmacy Tutorials and Cases with the Living Textbook.” Enriching Scholarship Program, University of
Michigan, Ann Arbor, Michigan. May 2004.
L. S. Welage - 31
“Management of Gram Positive Infections.” Nurse practitioners in the Grand Blanc/Flint area April 2004.
"Management of Gram Positive Infections." Department of Pharmacy, Port Huron Hospital, Port Huron, Michigan.
December 2003.
"Management of Gram Positive Infections." Physicians in Bay City/Midland, Michigan December 2003.
"Management of Gram Positive Infections." Saginaw, Michigan. October 2003.
“Management of Gram Positive Infections.” Department of Critical Care, Beaumont Hospital. Farmington Hills,
Michigan. September 2003.
“Acid Suppressant Therapy in the Hospital Setting.” Garden City Hospital, Garden City, Michigan. February 2003
“Acid Suppressant Therapy in the Hospital Setting.” Local area pharmacists. Dearborn, Michigan. February 2003
“Acid Suppressant Therapy in the Hospital Setting.” Departments of Nursing and Pharmacy, Kindred Hospital,
Livonia, Michigan. February 2003.
“Acid Suppressant Therapy in the Hospital Setting.” Department of Pharmacy, Bronson Hospital, Kalamazoo,
Michigan. February 2003
“Acid Suppressant Therapy in the Hospital Setting.” Department of Pharmacy, Borgess Hospital, Kalamazoo, MI.
February 2003
“Acid Suppressant Therapy in the Hospital Setting.” Department of Pharmacy Services, St. Johns Hospital, Detroit,
MI. November 2002.
“Update on Antifungal Therapy for Surgical Patients.” Department of Pharmacy Services, Covenant Harrison
Hospital, Saginaw, MI. September 2002.
“Acid Suppressant Therapy in the Hospital Setting.” Department of Pharmacy Service, Port Huron Hospital. Port
Huron, MI. August 2002.
“Acid Suppressant Therapy in the Hospital setting.” Department of Pharmacy Services, Troy Beaumont Hospital.
Troy, MI. August 2002.
“Clinical Use of Proton Pump Inhibitors in the Hospital Setting.” Department of Pharmacy Services, University of
Michigan. Ann Arbor, Michigan. July 2002.
“Acid Suppressant Therapy in the Hospital Setting.” Department of Pharmacy Services, Oakwood Hospital.
Dearborn, MI. June 2002
“Managing Systemic Fungal Infections.” Update on Infectious Diseases. Genesys Hospital. Flint, Michigan.
December 2001.
“Optimizing Antifungal Therapy.” Department of Pharmacy, Hurley Medical Center. Flint, Michigan. December
2001.
“Managing Systemic Fungal Infections: Selecting and Optimizing Drug Therapy.” Department of Pharmacy, Huron
Valley Sinai Hospital. Commerce, Michigan. November 2001.
“Managing Systemic Fungal Infections: Selecting and Optimizing Drug Therapy.” Department of Pharmacy. North
Oakland Hospital. Pontiac, Michigan. October 2001.
L. S. Welage - 32
“Managing Systemic Fungal Infections: Selecting and Optimizing Drug Therapy.” Department of Pharmacy, St.
Joseph Mercy Hospital. Pontiac, Michigan. September 2001.
“Antisecretory Therapy in the ICU: Preventing Stress Related Mucosal Bleeding and Managing Peptic Ulcer
Bleeding.” The University of Michigan College of Pharmacy Continuing Education Symposium entitled:
“Expanding Role of Proton Pump Inhibitors”. Ypsilanti, Michigan. September 2001.
“Proton Pump Inhibitors in the Hospital Setting.” Department of Pharmacy, Sparrow Hospital. East Lansing,
Michigan. June 2001.
“Managing Systemic Fungal Infections in Surgical Patients: Selecting and Optimizing Drug Therapy.” Southeastern
Michigan Society of Hospital Pharmacists. Southfield, Michigan. May 2001.
“Acid Suppressant Therapy in the Hospital Setting.” Northern Michigan Society of Health System Pharmacists.
Gaylord, Michigan. November 2000.
“Proton Pump Inhibitors in the Hospital Setting.” Medical Grand Rounds, Port Huron Hospital. Port Huron,
Michigan. June 2000.
“Update Regarding Fungal Infections.” Surgical Grand Rounds, St. Mary’s Hospital. Saginaw, Michigan. June
2000. “Update Regarding Fungal Infections in Surgical Patients: What Are the Issues in the Year 2000?” Beyer
Hospital. Ypsilanti, Michigan. April 2000.
“Clinical Use of Proton Pump Inhibitors in the Hospital Setting.” Oakwood Hospital, Dearborn, Michigan. February
2000.
“Antifungal Therapy for Surgical Patients.” Surgical Grand Rounds, St. Luke Hospital. Saginaw, Michigan. May
1998.
“Issues and Controversies Regarding Antifungal Therapy in Surgical Patients.” Western Michigan Society of
Hospital Pharmacists. Kalamazoo, Michigan. February 1998.
“Presumptive Antifungal Therapy.” Local area pharmacists. Flint, Michigan. May 1997.
“The Potential Role of the Gastrointestinal Tract in Nosocomial Pneumonia.” Detroit Receiving Hospital. Detroit,
Michigan. April 1994.
“Treatment of Gram Negative Sepsis.” Southeastern Michigan Society of Hospital Pharmacists. Southfield,
Michigan. September 1992.
“Principles of Antimicrobial Therapy for the Management of Intra-abdominal Infections.” Department of Surgery,
St. Joseph Mercy Hospital. Ann Arbor, Michigan. February 1992.
“Monoclonal Antibodies in the Management of Sepsis.” Western Society of Hospital Pharmacists. Grand Rapids,
Michigan. November 1991.
“Monoclonal Antibodies in the Management of Sepsis: What are the Emerging Pharmacy Issues?” Biotechnology
Symposium, Henry Ford Hospital. Detroit, Michigan. November 1991.
“New Advances in the Treatment of Acid-Peptic Disease.” KI Sawyer Air Force Base. Marquette, Michigan. June
1991.
“The Use of Monoclonal Antibodies in the Treatment of Sepsis.” Dearborn, Michigan. June 1991. “Drug
Interactions - A Consideration in Peptic Ulcer Disease.” Presented to Detroit Area Internists and
Gastroenterologists as part of the symposium entitled: Issues and Controversies in Gastrointestinal. Dearborn,
Michigan. November 1990.
L. S. Welage - 33
“An Update in the Management of GERD.” At Gastroenterologic Diseases Advances in Therapy. Annual Pharmacy
Lectures, University of Michigan. Ann Arbor, Michigan. October 1990.
Invited Regional Presentations:
(presented to pharmacists unless otherwise stated)
“GI Complications in the ICU.” MidAmerican Critical Care Conference (MACCs). Toledo, Ohio. September
2005.
“Optimizing Acid Suppressant Therapy in the Hospital Setting: Maximizing Appropriate Use of Proton Pump
Inhibitors.” Program to Physicians, Nurses and Pharmacists. Cleveland, Ohio. May 2005.
“Optimizing Acid Suppressant Therapy in the Hospital Setting: Maximizing Appropriate Use of Proton Pump
Inhibitors.” Program to Physicians, Nurses and Pharmacists. Columbus, Ohio. March 2005.
“Incorporating Clinical Evidence into Treatment Algorithms.” Multidisciplinary Continuing Education Symposium:
Acid Suppression in the ICU: Re-evaluating the Evidence (ASPIRE). Presented in Seattle, WA, St Louis MO, and
Washington DC. 2005.
"Stress Ulcers in the ICU: What We Should Tell Our Colleagues to Prevent the GI Consult." IMPACT, New York,
New York, April 2004.
"Understanding Alterations in GI Function in the Critically Ill." New England Critical Care Pharmacy Symposium
(sponsored by Northestern) Boston, Massachusetts, April 2004.
“Incorporating Clinical Evidence into Treatment Algorithms.” Multidisciplinary Continuing Educaiton Symposium:
Acid Suppression in the ICU: Re-evaluating the Evidence (ASPIRE). San Diego, California. January 2004.
“Acid Suppression in the ICU.” University of Wisconsin Continuing Education Program for Pharmacists. Madison,
Wisconsin. August 2003.
“Therapeutic Options for the Management of Acid Secretion.” Multidisciplinary Continuing Educaiton Symposium:
Acid Suppression in the ICU: Re-evaluating the Evidence (ASPIRE). San Francisco, California. February 2003.
“Acid Suppressant Therapy in the Hospital Setting.” Hartford, Connecticut. October 2002.
“Incorporating Clinical Evidence into Institutional Treatment Algorithms.” A Multidisciplinary Continuing
Education Symposium entitled: Acid Suppression in the ICU: Re-evaluating the Evidence). ASPIRE CE Speaker
Training. Wilmington, DE. July 2002.
“PPIs, Clinical and Hospital Formulary Issues.” Medical Grand Rounds, Riverside Hospital. Waupaca, Wisconsin.
May 2002.
“PPIs, Clinical and Hospital Formulary Issues.” Creighton University School of Pharmacy. Creighton, Nebraska.
May 2002.
“PPIs, Clinical and Hospital Formulary Issues.” Lincoln, Nebraska. May 2002.
“Clinical Use of Proton Pump Inhibitors in the Hospital Setting.” Omaha, Nebraska. May 2002.
“Role of Proton Pump Inhibitors in the Hospital Setting.” Presented to area physicians, Iron County Medical
Education Annual Program. Ski Brule, Wisconsin. February 2002.
L. S. Welage - 34
“Pathophysiology of Sepsis- the Potential Role of Activated Protein C.” Presented to area physicians, Iron County
Medical Education Annual Program. Ski Brule, Wisconsin. February 2002.
“The Role of Proton Pump Inhibitors in the ICU.” Medical Staff. Sacred Hearts – St. Mary’s Hospitals.
Rhinelander, Wisconsin. June 2001.
“Expanding Role of Proton Pump Inhibitors in the Hospital Setting.” Dwight Eisenhower Army Medical Center,
Fort Gordon, Georgia. March 2001.
“Clinical Use of Proton Pump Inhibitors in the Hospital Setting.” University of Georgia, School of Pharmacy. March
2001.
“Update on Pharmacologic Modalities Used to Control Acid Secretion in the ICU.” Howard Young Medical Center,
Woodruff, Wisconsin. February 2001
“Critical Care Issues.” Therapeutic Options in Acid Secretory Disease Management: The Use of Proton Pump
Inhibitors. California Society of Health System Pharmacists. Palm Springs, California. November 2000.
“Update on H2 Antagonists.” Fort Myers, Florida. February 1996.
“Management of Fungal Infections in the Surgical Population.” Illinois Council Hospital Pharmacist. Chicago,
Illinois. May 1995.
“Antibiotic Associated Coagulopathy and the Significance of Bacteroides Species B.D.O.T Group.” South Bend
Hospital Pharmacists. South Bend, Indiana. November 1993.
“Current Topics in Pharmacotherapy Sepsis.” Monoclonal Antibodies in the Treatment of Sepsis Teleconference
Network of Texas. The University of Texas Health Science Center at San Antonio. San Antonio, Texas. July 1993.
“Safety of Peptic Ulcer Diseases: Adverse Reactions and Drug Interactions.” University of Kentucky Continuing
Education Series. (Locations: Greensville, South Carolina; New York, New York; New Orleans, Louisiana; Seattle
Washington.) 1992.
“Pharmacologic Considerations in the Management of Peptic Ulcer Disease.” Ohio Physicians and Pharmacists- GI
Symposium. Akron, Ohio. November 1991.
“Nosocomial Pneumonia and Antiulcer Therapy: What are the Facts?” At New Approaches of the Treatment of
Gastrointestinal Disorders in Hospitalized Patients Symposium. Division of Pharmacy Practice at the School of
Pharmacy, University of Colorado Health Science Center. Denver, Colorado. October 1990.
“Stress Related Mucosal Damage: A Stepwise Approach to Therapy.” At Ulcer Disease: Issues and Controversies
Symposium. University of Cincinnati, College of Pharmacy. Covington, Kentucky. October 1990.
“H2 Antagonist Dilemma: How Should They Be Used?” Merck, Sharp & Dohme Gastrointestinal Symposium.
Sandusky, Ohio. August 1989.
Invited National Presentations:
(presented to pharmacists unless otherwise stated)
“Successful Programmatic Evaluation: Principles, Perspectives & Practices.” American Association of Colleges of
Pharmacy Annual Meeting. Kissimmee, Florida. July 2012.
“Case Studies of Pharmacists Engaged in Translational Research: NIH CTSA/CTSI Pilot Projects.” American
College of Clinical Pharmacy Annual Meeting. Albuquerque, New Mexico. October 2013
L. S. Welage - 35
“K Awards.” American College of Clinical Pharmacy, Focused Investigator Training, Athens, Georgia, July 2013
“Enhanced Investigator Training for Clinical Pharmacists: What are the Options?” American College of Clinical
Pharmacy Annual Meeting. Louisville, Kentucky. October 2008.
“Stress Ulcer Prophylaxis: Should Proton Pump Inhibitors be Started in All ICU Patients?” Society of Critical Care
Medicine Annual Meeting. Honolulu, Hawaii. February 2008.
“What’s New in GERD Therapy: A Case-Based Approach. Gastroesophageal Reflux Disease and Nocturnal
GERD.” American Society of Health System Pharmacists Annual Meeting. Anaheim, California. December 2006.
“Stress Ulcer Prophylaxis and Pharmacotherapy for Acute GI Bleed.” Society of Critical Care Medicine
Pharmacotherapy Course. Chicago, Illinois. November 2005.
“Recognition of Reflux Disorders: What Questions Remain? Therapeutic Options: Existing and Evolving
Formulations in Acid Suppression.” Satellite Symposium Digestive Disease Week. Chicago, Illinois. May 2005.
“Clinical Challenges and Evidence Based Solutions: Acid Suppression in the ICU. Effective Stress Ulcer
Prophylaxis: What’s Best.” Daybreak Symposium, Society of Critical Care Medicine Annual Meeting. Phoenix,
Arizona. January 2005.
“Pharmacologic Principles of Acid Suppression.” Satellite Symposium, American Society Health System
Pharmacists Annual Meeting. Orlando, Florida. December 2004.
“A Rational Approach to Acid Suppression: Pharmacologic Basis and Endpoints.” Navigating the Maze: Challenges
and Choices in Acid Suppression Satellite Symposium, American College of Gastroenterology Annual Meeting.
Orlando, Florida. October 2004.
“H2 Receptor Antagonists are Preferred Over Proton Pump Inhibitors for Prophylaxis of Stress Related Mucosal
Damage.” American College of Clinical Pharmacy Annual Meeting. Dallas, Texas. October 2004.
“Resolving the Unanswered Questions of Acid Suppression in the Hospital Setting. Managing Peptic Ulcer Disease
Rebleeding Understanding and Applying the Evidence.” Exhibitor Classroom at the American College of Clinical
Pharmacy Annual Meeting. Dallas, Texas. October 2004.
"The Future of Acid Suppression: Pharmacology of PPIs." Digestive Disease Week, Satellite Symposium, New
Orleans, Louisiana. May 2004
“Key Controversies in Critical Care Patient. Gut of the ICU Patient. Point Counterpoint.” Society of Critical Care
Medicine Annual Meeting. February 2004.
"Pathogenesis of PUD Bleeding and Stress Related Mucosal Bleeding," ASHP Midyear. New Orleans, Louisiana.
December 2003
"Potential Role of Erythropoietins in the ICU." ASHP Midyear. New Orleans, Louisiana. December 2003.
“Designing Treatment Algorithms for Acid Suppression in the ICU.” American Society of Health System
Pharmacists. Web-based continuing education program. September 2003.
“H2RA and PPI Use in the ICU: Issues to Consider. Data for Decision Makers: Management of GI Complications in
Critical Care” an Exhibitor Classroom, at the American College of Clinical Pharmacy Spring Meeting. Palm
Springs, California. April 2003.
“Controversies in the Management of Upper Gastrointestinal Bleeding.” Exhibitor Classroom, at the American
L. S. Welage - 36
College of Clinical Pharmacy Spring Meeting. Palm Springs, California. April 2003
“Pathophysiology of Sepsis.” American Pharmaceutical Association Annual Meeting. New Orleans, Louisiana.
March 2003.
“Impact of Disease on Drug Disposition.” American Society of Health System Pharmacists. Atlanta, Georgia.
December 2002.
“Using Pharmacologic Principles to Maximize PPI Benefit.” Acid Suppression in the ICU: Integrating Physiology
and Clinical Evidence, an Exhibitor Classroom, at the American College of Clinical Pharmacy Annual Meeting.
Albuquerque, New Mexico. October 2002.
“Are All PPIs the Same? The Pharmacologic Perspective.” Challenging Current Paradigms Satellite
Symposium. Digestive Disease Week. San Francisco, California. May 2002.
“Practical Implications of Using Proton Pump Inhibitors in the ICU.” GI Bleeding in the Critical Care Setting:
Proper Patient Management and the Role of Pharmacotherapy Sunrise Session at the American Association of
Critical Care Nurses National Teaching Institute and Critical Care Exposition. Atlanta, Georgia. May 2002.
“Clinical Relevance of Pharmacologic Factors Affecting Proton Pump Inhibitor Activity.” Evolving Science of
Acid Suppression Satellite Symposium. American College of Clinical Pharmacy Spring Forum. Savannah,
Georgia. April 2002.
“Concepts in Gastric Acid Secretion: Differentiating Among Therapeutic Approaches.” Pri-Med Multidisciplinary
Symposia: Rethinking GERD: Incorporating Recent Scientific Findings into Clinical Practice. Reston, Virginia.
March 2002.
“Clinical Pharmacology 101: Beware of the ICU.” Presented to Critical Care Fellows at the Society of Critical Care
Medicine Meeting. San Diego, California. January 2002.
“Role of Low Molecular Weight Heparin in Critically Ill Patients.” American Society of Health Systems
Pharmacists. Midyear Meeting. New Orleans, Louisiana. December 2001.
“Pathophysiology of Sepsis.” American Society of Health System Pharmacists. Midyear Meeting. New Orleans,
Louisiana. December 2001.
The Expanding Role of Proton Pump Inhibitors in the Hospital Setting: Health Systems Corporation of America.”
Teleconference. November 2001.
“A New Look at the Pharmacology of Proton Pump Inhibitors.” New Concepts in Acid Suppressors in the
Hospitalized Patient. Satellite Symposium. American College of Clinical Pharmacy Annual Meeting. Tampa,
Florida. October 2001.
“New Insights into the Evolving Treatment of Acid Related Disorders.” GE-Medical Systems TIPS - TV. TV
broadcast to Hospitals Across U.S. October 2001.
“Decision Making Regarding Acid Suppressor Therapy: Utilizing an Evidence Based Approach.” Breakfast
Symposium American Society of Health System Pharmacists Annual Meeting. Los Angeles, California. June 2001.
“Pharmacologic Features of PPIs and their Relevance to Clinical Practice.” Progress Toward Disease Resolution:
Have We Improved the Treatment for GERD and Other Acid Related Disorders Satellite Symposium. Digestive
Disease Week. Atlanta, Georgia. May 2001.
“Do Critically Ill Patients with H. Pylori Have Increased Risk for GI Bleeding.” American College of Clinical
Pharmacy Spring Meeting. Salt Lake City, Utah. April 2001.
L. S. Welage - 37
“Update on Pharmacologic Modalities Used to Control Acid Secretion in the ICU.” Society of Critical Care
Medicine Annual Meeting. San Francisco, California. February 2001.
“PPIs: Clinical and Hospital Formulary Issues.” State University of New York School of Pharmacy Continuing
Education Teleconference Series offered to pharmacists across the United States. 2001-2003.
“Acid Suppression in the ICU Patient.” State University of New York School of Pharmacy Continuing Education
Teleconference Series offered to pharmacists across the United States. 2001-2003.
“Advances in Hospital Based Acid Suppression.” Breakfast and CE. ASHP Midyear Meeting. Las Vegas, Nevada.
December 2000.
“The Pharmacologic and Pharmacokinetic Basis of Current and Future PPIs.” Optimizing Therapeutic Management
of GERD: Symptomatic Relief or Disease Resolution Satellite Symposium, American College of Gastroenterology.
New York, New York. October 2000.
“Challenges in the Use of Antisecretory Therapy in the Hospital Setting.” Live Broadcast, VHA. Irving, Texas.
October 2000.
“Intravenous Acid Suppression in the Hospital Setting.” American Society of Health System Pharmacists, web
based continuing education program (www.ashp.org/public/ceonline/wyeth/acid-supp.html). May 2000.
“Acute Aggressive Acid Suppressive Therapy: Mechanisms of Altered Patient Response in Acute Disease: Influence
in Drug Therapy.” American College of Clinical Pharmacy. Monterey, California. April 2000.
“Prophylaxis for Acute Stress Related Mucosal Damage.” American College of Clinical Pharmacy. Monterey,
California. April 2000.
“Antisecretory Therapy in High Risk Critical Care Patients.” Acid Suppression in the Critically Ill Symposium,
Society of Critical Care Medicine 29th Annual Education and Scientific Symposium. Orlando, Florida. February
2000.
“Oral Drug Delivery in the Critically Ill: Is it a Good Thing?” Society of Critical Care Medicine 29th Annual
Education and Scientific Symposium. Orlando, Florida. February 2000.
“Clinical Use of Proton Pump Inhibitors in the Hospital Setting.” American Society Health System Pharmacists
Midyear Meeting. Orlando, Florida. December 1999.
“Issues and Controversies Regarding Antifungal Therapy.” Teleconference to pharmacists across the United States.
April 1999.
Panelist: “Clinical Management Strategies.” Society of Critical Care Medicine 28th Educational and Scientific
Symposium. San Francisco, California. January 1999.
“Therapeutic Approaches to Resistant Pathogens.” Society of Critical Care Medicine 28th Educational and
Scientific Symposium. San Francisco, California. January 1999.
“Acid Suppressant Therapy in the Hospital Setting.” American Society Health System Pharmacists, Midyear
Meeting. Las Vegas, Nevada. December 1998.
“Acid Suppressant Therapy in the Hospital Setting.” Therapeutic Update Regarding Acid Suppression Symposium,
American College of Clinical Pharmacy. Cincinnati, Ohio. November 1998.
“Role of New Antimicrobial Agents in Managing Nosocomial Pneumonia.” American College of Clinical
Pharmacy Spring Symposium. Palm Springs, California. April 1998.
L. S. Welage - 38
Panelist, Interactive Case Presentations, Society of Critical Care Medicine Annual Meeting. San Antonio, Texas.
February 1998.
“Disease and Oral Dosage Form Performance.” AAPS/CRS/FDA Workshop on Scientific Foundation and
Applications for the Biopharmaceutics Classification System and In Vitro-In Vivo Correlations. Arlington,
Virginia. April 1997.
“Peptic Ulcer Disease - A Model for Population Based Outcomes Research.” Academy of Managed Care
Pharmacists, Annual Meeting. Fort Lauderdale, Florida. November 1996.
“Management of Fungal Infections in Surgical Patients.” Teleconference presented to pharmacists across the United
States. October 1996.
“Developing, Refining and Implementing Appropriate Use Strategies that Work.” American Society of Health
System Pharmacists, Annual Meeting. San Diego, California. June 1996.
“Principles of Selective Decontamination of the Digestive Tract.” Teleconference presented to pharmacists across
the United States. March 1994.
“Gastric Acid Inhibitors and Gastroesophageal Reflux Disease.” Advances in the Treatment of Gastroenterologic
Disorders. Satellite Symposium, American College of Clinical Pharmacy Annual Meeting. Reno, Nevada. August
1993.
“Antiendotoxin Antibody and Gram Negative Sepsis.” Annual Meeting of New York State College of Clinical
Pharmacy of ACCP. Syracuse, New York. May 1992.
“Intra-abdominal Infections.” Teleconference to pharmacists across the United States. June 1991.
“Management of Reflux Esophagitis.” Teleconference sponsored by University of Texas Health Science Center.
San Antonio, Texas. June 1991.
Invited International Presentations:
“Pharmacy in the U.S.” Presented at the XLVII Congreso Nacional de Ciencias Farmaceuticas de Asociacion
Farmaceutica Mexicana (XLVII National Congress of Pharmaceutical Sciences of the Mexican Pharmaceutical
Association), Puerto Vallarta, Jalisco, Mexico, October 2014.
“3rd Meeting Facultad de Farmacia UAEM-College of Pharmacy UNM-UAEM”, Moreles, Mexico. November
2013.
“Unraveling Mechanisms and Consequences of Drug Interactions” GASTRO 2009 UEGW/WCOG Joint
Conference. London, UK November 2009.
“Issues to Consider When Designing a Doctor of Pharmacy Curriculum.” The Arabic Regional Conference on the
Future of Pharmacy Education and Practice in the Arab World. Damascus, Syria. November 2007.
“Designing and Managing the Experiential Training Program.” T The Arabic Regional Conference on the Future of
Pharmacy Education and Practice in the Arab World. Damascus, Syria. November 2007.
“Data Collection and Analysis.” Research Proposal Writing Workshop. Presented to students and faculty.
Kalamoon University, Syria. May 2007.
“Ensuring Patient Safety in Clinical Research.” Research Proposal Writing Workshop. Presented to students and
faculty. Kalamoon University, Syria. May 2007.
L. S. Welage - 39
“Transforming Ideas into Research Projects.” Research Proposal Writing Workshop. Presented to students and
faculty. Kalamoon University, Syria. May 2007.
“Integrating Research into the Curriculum.” Research Proposal Writing Workshop. Presented to students and
faculty. Kalamoon University, Syria. May 2007.
“Therapeutic Options for the Management of Acid Secretion.” Multidisciplinary Continuing Education Symposium
entitled: Acid Suppression in the ICU: Re-evaluating the Evidence. Puerto Rico. March 2004.
“Gastrointestinal Motility, GI Transit and Absorption.” International Program on Strategies for Oral Drug Delivery.
Lake Tahoe, Nevada. March 2002.
“Disease State and Drug Absorption.” International Program on Oral Drug Delivery, Biopharmaceutic and
Pharmacokinetic Strategies. Lake Tahoe, Nevada. March 2002.
“Disease States and Drug Absorption.” International Program on Strategies for Oral Drug Delivery. GarmischPartenkirchen, Germany. March 2001.
“Gastrointestinal Motility, GI Transit and Absorption.” International Program on Strategies for Oral Drug Delivery.
Garmisch-Partenkirchen, Germany. March 2001
“In Situ Perfusions.” International Program on Oral Drug Delivery, Biopharmaceutics and Pharmacokinetic
Strategies.” Lake Tahoe, Nevada. March 2000. International Educational Symposium on oral Drug Delivery, the
program location rotates between the United States, Germany and Sweden.
“Disease State and Drug Absorption.” International Program on Oral Drug Delivery, Biopharmaceutic and
Pharmacokinetic Strategies. Lake Tahoe, Nevada. March 2000. International Educational Symposium on oral Drug
Delivery, the program location rotates between the United States, Germany and Sweden.
“Gastrointestinal Physiology.” International Program on Oral Drug Delivery, Biopharmaceutic and
Pharmacokinetic Strategies. Lake Tahoe, Nevada. March 2000. International Educational Symposium on oral
Drug Delivery, the program location rotates between the United States, Germany and Sweden.
“Food Effects on Drug Absorption.” International Program on Oral Drug Delivery, Biopharmaceutic and
Pharmacokinetic Strategies. Uppsala, Sweden. August 1998.
“Disease States and Drug Absorption.” International Program on Oral Drug Delivery, Biopharmaceutic and
Pharmacokinetic Strategies. Uppsala, Sweden. August 1998.
“Gastrointestinal Variables: Luminal Variable.” International Program on Oral Drug Delivery, Biopharmaceutic and
Pharmacokinetic Strategies. Baltimore, Maryland. October 1997.
“Disease States and Drug Absorption.” International Program on Oral Drug Delivery, Biopharmaceutic and
Pharmacokinetic Strategies. Baltimore, Maryland. October 1997.
“In Vivo Permeability Measurements.” International Program on Oral Drug Delivery, Biopharmaceutic and
Pharmacokinetic Strategies. Ann Arbor, Michigan. October 1995.
“Monoclonal Antibodies in the Management of Gram Negative Sepsis.” 4th Annual Canadian Symposium of
ACCP, Banff. Alberta, Canada. March 1992.
“Current Issues in Stress Ulcer Prophylaxis.” Canadian Society of Hospital Pharmacists, Critical Care Symposium.
Vancouver, British Columbia. August 1991.
L. S. Welage - 40
Other Invited Presentations:
“Managing Systemic Fungal Infections.” Pfizer/Powers Pharmaceutical Representatives. Ypsilanti, Michigan.
October 2001.
“Trovafloxacin A New Fluoroquinolone: What Will It’s Role Be?” Pfizer-Roerig and Powers-Michigan Field
Forces. Ypsilanti, Michigan. December 1997.
“Issues and Controversies Regarding Antifungal Therapy in Surgical Patients.” Powers-Michigan Field Force.
Ypsilanti, Michigan. November 1997.
“Issues and Controversies in Antifungal Therapy in the Surgical Population.” Pfizer, Michigan Field Force.
Ypsilanti, Michigan. February 1997.
SERVICE
Clinical Service:
1988 – 2006
Clinical Pharmacist, Trauma Burn Center, University of Michigan Medical
Center, Ann Arbor, Michigan
The University of Michigan Trauma Burn Center, is a level one trauma
center (verified by the American College of Surgeons) that serves the
people of Michigan and surrounding states. A multidisciplinary trauma
team composed of physicians, nurses, clinical pharmacists, social workers
and occupational therapists work together to provide exceptional care to
adult trauma victims, as well as adult and pediatric burn victims.
Approximately 1,100 emergent and acute trauma and burn patients are
admitted to the Center annually. In addition to providing care to the
patients and their families, the multidisciplinary team works together to
educate the public and various health professionals regarding the
prevention and management of acute injuries.
1986 – 1988
Clinical Pharmacist, and Program Director of Critical Care, Clinical
Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, New
York
As Program Director of Critical Care, Dr. Welage was responsible for
clinical pharmacy services and clinical research within the surgical
intensive care unit. In addition, she was a member of the Clinical
Pharmacokinetics Consult Service. The Service was responsible for
managing aminoglycoside and vancomycin dosing upon request of the
physician.
Committees:
University of New Mexico College of Pharmacy Committees
Jan
2013
to 2014
College of Pharmacy Website Steering Committee (Chair)
Apr
2012
to present
College of Pharmacy Promotion and Tenure Dean’s Advisory
Committee
Feb
2011
to present
Budget and Planning Committee
Oct
2011
to present
Student Pharmacist Executive Advisory Roundtable
Oct
2011
to present
Ex Officio Curriculum Committee
L. S. Welage - 41
Oct
2011
to
present
Dean’s Executive Leadership Committee
University of New Mexico Health Science Center Committees
May 2015
to present
HSC UNM West Committee
Mar 2014
to present
HSC Interprofessional Healthcare Simulation Advisory Committee
Sept 2013
to 2014
UNM HSC American Indian Health Opportunities-Council of
American Indian Leaders (CAIL)
Aug 2013
to 2014
Search Committee- Associate Vice Chancellor for Diversity, Health
Science Center
Apr
2013
to present
Health Science Center Workforce Group
Jan
2013
to present
Health Science Center Health Policy Committee
Sept 2012
to present
Health Science Center Core Group
Sept 2012
to present
Health Science Center Leadership Group
Sept 2012
to present
Office of Diversity Faculty of Color Leadership Planning Committee
Sept 2012
to present
Health Science Center Academic Deans’ Committee
Oct
2012
to present
Sandoval Regional Medical Center Academic Engagement Committee
Feb
2012
to Aug
2014
Health Science Center Mentoring- Faculty of Color Pilot Program
Steering Committee
Oct
2011
to Sept
2012
Health Science Center Executive Council
2012
Health Science Center Deans’ Committee
Oct 2011 to Sept
Health Science Center Information Technology Leadership Committee
Oct 2011 to present
2011
to
present
Health Science Center Executive Compliance Committee
Oct New Mexico Poison and Drug Informatics Center Financial Advisory
Oct 2011 to present
Committee
University of New Mexico Committees
Sept 2013
to Sept
2015
May 2013
to Dec
2013
Apr
2013
to Aug
2013
May 2013
to present
May 2013
to present
Feb
2013
to Dec
2015
Dec
2012
to Aug
2013
College of Public Health Planning Structure Committee
Search Committee- Director, UNM Robert Wood Johnson Foundation
Gulf of Lomas Committee
UNM Deans’ Only Deans’ Council
Deans’ Council (open)
Development and Alumni Strategic Council
Provost’s Steering Committee for UNM Robert Wood Johnson
Foundation Center
Central New Mexico Community College
Jan
2012
to present
Central New Mexico Pharmacy Technician Advisory Committee
University of Michigan College of Pharmacy Committees
Sept 2009
to Dec
2009
Ad Hoc Promotion Review Committee- Dept. of Clinical Sciences
Sept 2008
to Oct
2011
Chair, Accreditation self-study
Sept 2006
to Oct
2011
International Steering Committee
Dec
2006
to July
2007
Ad Hoc Committee for Merger of College of Pharmacy Department
Nov 2005
to Apr
2007
Center for Molecular Drug Targeting Advisory Board
Sept 2005
to Dec
2007
Clinical Pharmacogenomics Laboratory Advisory Board
Sept 2005
to June
2006
Chair, Ad Hoc Committee on Student Mentoring
Aug 2005
to Oct
2005
Ad Hoc Promotion Review Committee- Dept. of Clinical Sciences
Aug 2005
to Nov
2005
MTMS Committee
Sept 2004
to Oct
2011
Chair, Student Leaders Forum
Sept 2004
to Oct
2011
Executive committee (ex officio, without vote)
2011
Chair, Academic Standing Committee
Sept 2004
to Oct
Sept 2004
to Oct
2011
Admissions Committee
Sept 2004
to Oct
2011
Budget Planning Group
2005
Space Allocations Committee
Sept 2004
to Aug
May 2004
to Oct
2011
Policy Review Committee
L. S. Welage - 42
May
Oct
July
Mar
July
Jan
Dec
Dec
Sept
July
Jan
June
June
2003
2002
2002
2002
2001
2001
2000
1999
1999
1999
1998
1998
1998
to to to to to to to to to to to to to Dec
Feb
Aug
Jan
Aug
Apr
May
Feb
Aug
Aug
Feb
May
Apr
2003
2004
2004
2004
2004
2001
2001
2000
2001
2002
2000
1999
1999
July
July
Apr
Apr
Oct
Oct
Sept
July
Jan
July
Mar
1997
1997
1997
1997
1996
1996
1996
1996
1996
1995
1995
to to to to to to to to to to to June
June
Dec
Dec
Aug
Aug
Sept
June
Dec
June
Nov
1998
2000
1997
1997
1997
1997
1997
2001
1997
2002
1995
Jan
Jan
June
Aug
July
June
June
June
1994
1994
1993
1993
1993
1992
1992
1992
to to to to to to to to Nov
Mar
Aug
Aug
Aug
Oct
June
May
1995
1994
1994
1994
1993
1997
1997
1992
July
July
July
July
1991
1991
1990
1989
to to to to Oct
May
Oct
Sept
1996
2002
1991
1991
Dean Search Advisory Committee
Search Committee - Director of Experiential Training
Experiential Training Committee
Redesign of Drug Information/Scientific Literature Evaluation
Teaching Effectiveness Committee
College of Pharmacy Research Structure and Enhancement
Search Committee - Director Practitioner Relations
Search Committee - TPN/Surgery Clinical Pharmacist
Experiential Training Committee
Chairman, Curriculum Committee
Chairman, Search Committee Division Chair for Clinical Sciences
Search Committee - Surgery Clinical Pharmacist
Search Committee - Director of Pharmacy Services and Associate Dean
for Clinical Sciences
Strategic Planning Committee
College of Pharmacy Executive Committee
Dean Search Advisory Committee
Search Committee - OR Pharmacist
Curriculum Committee Subcommittee on Therapeutics
Curriculum Committee Subcommittee on Patient Monitoring
Curriculum Committee Subcommittee on P4 Portfolio
Clinical Research Resources Committee
Chairman, Practice Faculty Committee College Websites
Curriculum Committee
Chairman, Subcommittee to the Curriculum Committee for Integration
of Pathophysiology/Therapeutics, Nonprescription Drugs and Applied
Pharmacokinetics
Search Committee - Trauma Burn/Transplant Clinical Pharmacist
Search Committee - Faculty Position in Pharmaceutical Analysis
Search Committee – Operating Room Clinical Pharmacist
Search Committee - Operating Room Pharmacy Supervisor
Search Committee - Target Drug Clinical Pharmacist
Space Allocations Committee
Computer Committee
Practice Faculty Subcommittee of the Curriculum Committee for the
review of Pharmacology
Pharm.D. Research Committee
Diversity Committee
Publications Committee
Practitioner Relations Committee
UNIVERSITY OF MICHIGAN DEPARTMENT OF PHARMACY, UNIVERSITY OF MICHIGAN
HEALTH SYSTEM COMMITTEES
Sept 2001
to Sept
2002
Department of Pharmacy Services Committee on Weekend Clinical
Coverage
July 2001
to Dec
2001
University of Michigan Medical Center Committee on Activated
Protein C Guidelines
July 2000
to Feb
2001
Search Committee – Infectious Diseases Pharmacist
June 2000
to Oct
2000
Pharmacokinetic Dosing Service
Jan
1998
to Aug
2000
Pharmacy Residency Advisory Committee
Sept 1996
to Feb
1997
General Clinical Research Committee
May 1992
to June
1998
Trauma Quality Assurance Committee
Mar 1992
to June
1995
Pharmacokinetics Pharmacy Subcommittee
Feb
1992
to June
1995
Total Quality Team on Pharmacokinetics
Aug 1991
to June
1995
Quality Assurance Pharmacy Laboratory Committee
July 1989
to July
1991
Pharmacy Residency Advisory Committee
L. S. Welage - 43
UNIVERSITY OF MICHIGAN COMMITTEES
Nov 2010
to Oct
2011
University of Michigan Medical School Accreditation Committee
Jan
2008
to May
2009
Multidisciplinary Health Education Center- Pilot Case Development
Sept 2006
to June
2007
Global Health Research Training
Dec
2005
to May
2009
Task Force on Multidisciplinary Learning and Teaching
Oct
2005
to Jan
2006
Multidisciplinary Committee to Develop China Curriculum
Sept 2005
to Apr
2006
Task Force on the Professional Degree in Nursing
Sept 2004
to Oct
2011
Vice Provosts/Associate Deans Group
Sept 2005
to Feb
2006
Director of Health Science Library Search -Faculty Interview Group
Sept 2004
to June
2005
Director of Health Science Library Search -Faculty Interview Group
Sept 2003
to Aug
2008
Advisory Committee, Mentored Clinical Research Scholar Program
Award (K12)
July 2000
to Aug
2008
Curriculum Committee, Clinical Research Training Program (K30)
Aug 1999
to Aug
2008
Advisory Committee, Clinical Research Training Program (K30)
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH COMMITTEES
July 2009
to June
2011
MICHR, Executive Cabinet
Jan
2010
to June
2011
MICHR Education Leadership Committee
Nov 2005
to Sept
2007
Clinical and Translational Science Award Initiative- Grant
Development
Sept 2007
to July
2009
MICHR Operating Committee
Sept 2007
to July
2009
MICHR Executive Committee for Education and Mentoring Programs
Sept 2007
to June
2011
MICHR Regulatory Affairs Committee
Sept 2007
to June
2011
MICHR Ethics Committee
Aug 2008
to June
2011
Unified Curriculum Committee
Aug 2008
to June
2011
Admissions Committee for Education MICHR
Aug 2008
to July
2009
MICHR Education Program Advisory Committee
STATE COMMITTEES – MICHIGAN
Sept 2004
to Oct
2011
Michigan Joint Commission on Pharmacy Practice
July 2003
to Mar
2004
Michigan Pharmacist Association, Education Committee
July 2003
to Sept
2004
Michigan Pharmacists Association, Community Pharmacy Task Force
STATE COMMITTEES – NEW MEXICO
Jan
2012
to present
New Mexico Pharmacists Association Executive Council
Jan
2012
to present
New Mexico Pharmaceutical Care Foundation
NATIONAL COMMITTEES
American Association of Colleges of Pharmacy:
July 2016
to present
AACP Council of Deans’ Task Force on Population Health
Mar 2013
to Dec
2013
Dean’s Council-Nomination Committee
American College of Clinical Pharmacy:
Oct
2013
to Sept
2014
American College of Clinical Pharmacy Research Affairs Committee
(Chair)
Oct
2011
to Oct
2012
American College of Clinical Pharmacy Research Affairs Committee
Feb
2003
American
College of Clinical Pharmacy Grant Review Committee
Oct
2002
to Feb
2003
American College of Clinical Pharmacy Fellowship Review Committee
2002
American College of Clinical Pharmacy Awards Committee
Nov 2001
to Oct
Oct
1999
to Apr
2001
American College of Clinical Pharmacy, Task Force on Research as the
Foundation for Pharmacy Practice
1999
Chairman, American College of Clinical Pharmacy, Research Affairs
Nov 1998
to Oct
Committee
Nov 1997
to Nov
1998
American College of Clinical Pharmacy, Critical Care Practice and
L. S. Welage - 44
Aug
1996
to Nov
1997
Feb
Feb
Feb
1996
1993
1992
to to to Nov
Feb
Feb
1997
1995
1995
Network Research Committee
American College of Clinical Pharmacy, Critical Care Practice and
Network Newsletter Committee Chairman
American College of Clinical Pharmacy, Clinical Affairs Committee
American College of Clinical Pharmacy, Educational Committee
American College of Clinical Pharmacy, Regional Membership
Recruiter
American Society of Health-System Pharmacists:
1992
to 1993
American Society of Health-System Pharmacists, Infectious Disease
Fellowship Selection Committee
AstraZeneca:
2001
AstraZeneca Clinical Pharmacy Research Awards, Review Committee
Clinical Translational Science Award Consortium:
July 2007
to June
2011
Education Key Function Committee
Oct
2009
to June
2011
Evaluation Key Function Committee
Oct
2009
to June
2011
Education-Evaluation Working Group
MidAmerican Critical Care Conference:
1998
to 2005
Educational Program Planning Committee for the annual Critical Care
Pharmacy Symposium (MACCS)
Society of Critical Care Medicine:
Jan
2006
to Jan
2009
Jan
2005
to Jan
2006
Jan
2005
to Jan
2006
July
2004
to Nov
2005
June
2003
to Nov
2004
Feb
2004
to Jan
2005
Jan
2003
to Feb
2004
Jan
2003
to Jan
2006
Jan
2003
to
Jan
2003
Aug
2001
to Dec
2003
Feb
2000
to Jan
2002
Oct
Oct
1999
1999
to to Feb
Feb
2003
2003
Aug
1996
to Feb
1998
Nominating Committee, Society of Critical Care Medicine
Past Chair, Clinical Pharmacy and Pharmacology section, Society of
Critical Care Medicine
Chairperson, Task Force on Mentoring, Clinical Pharmacy and
Pharmacology section of Society of Critical Care Medicine
Chairperson, Society of Critical Care Medicine, Program Committee
for 2005 Pharmacology Course
Society of Critical Care Medicine, Program Committee for 2004
Pharmacology Course
Chair, Clinical Pharmacy and Pharmacology section, Society of
Critical Care Medicine
Chair-elect Clinical Pharmacy and Pharmacology section, Society of
Critical Care Medicine
Advisory Committee, Clinical Pharmacy and Pharmacology Section of
Society of Critical Care Medicine
Clinical Pharmacy Pharmacology, Society of Critical Care Medicine
Task Force on Pharmacy Workload Issues
Chairman, Clinical Pharmacy and Pharmacology Grant Review
Committee, Society of Critical Care Medicine
Society of Critical Care Medicine, Clinical Pharmacy and
Pharmacology Continuing Pharmacy Education
Society of Critical Care Medicine, Program Committee
Society of Critical Care Medicine, Clinical Pharmacy and
Pharmacology
Education Committee
Society of Critical Care Medicine, Founders Fellowship Review
Committee
L. S. Welage - 45
PROFESSIONAL ORGANIZATIONS








American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society of Health System Pharmacists
International Pharmaceutical Federation
New Mexico Pharmacists Association
New Mexico Society of Health System Pharmacists
Society of Critical Care Medicine